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                                                                                                                    Introduction 
1. Introduction 
1.1 Cytokines and their Importance in Inflammatory Processes Cytokines 
 
Cytokines are small proteins, often glycoproteins, with molecular weights ranging 
from 8 to 40 kD. They serve as biochemical messengers between cells (cytokine is 
derived from the Greek words for cell and kinesis) and are involved in processes 
such as regulation of the immune response (host response to disease or infection), 
stress responses, cell growth/differentiation, and tissue repair. 
A single cytokine can exert numerous and various biological activities.  Most of the 
cytokines are made by leukocytes and act on other leukocytes. That is the reason  
why they are also called interleukins (IL). But these mediators can also serve to 
communicate signals between immune and nonimmune cells so the name interleukin 
is not adjective. 
Cytokines can be divided into four groups: α-helical cytokines (e.g. IFNγ), long-chain-
β-sheet cytokines (e.g. IL-1 family and TNF family), α/β-cytokines ( e.g. EGF family), 
and finally mosaic cytokines (e.g. IL-12). The maximal homology  between selected 
cytokines in one group is not more than 20% to 30%. Several properties are shared 
by structurally diverse cytokines. Actions of cytokines can often be called pleiotropic 
and redundant. The ability of one cytokine to act on different cell types mediating 
diverse biologic effects is called pleiotropism. Synthesis and actions of cytokines are 
influenced by other cytokines. Several cytokines may interact to antagonize each 
other’s action or to produce additive or synergistic effects. Additionally, the ability of 
one cytokine to induce the synthesis of others leads to the development of cytokine 
cascades. In these cascades the biologic effects may be mediated by a second or 
third cytokine of the upstream mediator. Cytokine actions can be locally or systemic. 
In most cases they act close to where they are produced in a autocrine or paracrine 
manner.  
By binding to specific membrane receptors on target cells, cytokines initiate their 
function. To elicit biological effects only relative small quantities of a cytokine are  
sufficient. Different classes of cytokine receptors are known. Namely class I-IV 
cytokine receptors, the receptor kinase family, and the chemokine receptors. 
Receptor expression is an important regulatory parameter in cytokine biology. For 
example, increased expression of cytokine receptors is induced by stimulation of T or 
B lymphocytes with antigens. Receptor expression is also regulated by cytokines 
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themselves. This can be managed by other members of the cytokine family or even 
the same respective cytokine, permitting positive or negativ feedback. Cellular 
responses to most cytokines in general mediate changes in gene expression, 
resulting in new cellular functions which can be accompanied by proliferation or 
differentiation. Chemokines, which elicit rapid cell migration without new gene 
expression, and tumor necrosis factor (TNFα), which may induce cell death without 
requiring new protein synthesis are exceptions to this rule.  
Secretion of cytokines is a short, self-limited event. A transient induction of de novo 
gene transcription is usually necessary to mediate their production. This process is a 
result of cellular activation by immune signals or stress. One reason for de novo gene 
transcription is the unstability of most messenger RNAs encoding cytokines. The 
production of some cytokines may be controlled by RNA processing and additionally 
by posttranscriptional mechanisms, such as proteolytic release of an active product 
from an inactive precursor (e.g. pro-IL-1β ).  Due to their influence on inflammatory 
processes cytokines can be divided into two groups.  
The most important immunoregulatory cytokines are listed in the following table: 
  Figure 1 
Proinflammatory
Cytokines
IL-1
TNFα
IL-8
IL-18
.
.
.
Antiinflammatory
Cytokines
IL-1Ra
IL-4
IL-6
IL-10
IL-13
IL-18BP
TGF-β
Soluble cytokine receptors
.
.
.
 
 
 
 
 
 
 
 
 
 
First the proinflammatory cytokines  which have the potential to make inflammatory 
disease worse. Second the antiinflammatory cytokines which serve to reduce 
inflammation and promote healing. The balance of pro- and antiinflammatory 
cytokines is dynamic. It is an ever-shifting process in which the amount of one 
cytokine-type can determine the kinetic and outcome of an inflammatory response. 
The human immune response is also regulated by specific cytokine inhibitors and 
soluble cytokine receptors. Furthermore, the net effect of any cytokine is dependent 
on several factors: the timepoint of cytokine release or the local milieu in which it 
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acts, the presence of competing or synergistic elements, cytokine receptor density, 
and tissue responsiveness to each cytokine. (Dinarello C.A. and Moldawer L.L., 
2000; Janeway C.A. and Travers P., 1997; Abbas A., 2000)  
 
 
1.1.2 Proinflammatory and Antiinflammatory Cytokines 
 
As explained above, cytokines can be divided into proinflammatory and 
antiinflammatory cytokines. In healthy persons proinflammatory cytokines are 
produced at low levels. When they are secreted at higher levels they induce a 
cascade of gene products. Such genes can be for example the type II A 
phospolipase (PL) A2, inducible nitric oxide (NO) synthase (iNOS), adhesion 
molecules, and IL-8.  Enzymes for which the genes are coding are responsible for an 
increased synthesis of prostaglandins, leukotrienes, NO, O2
-, matrix metallo-
proteinases (MMPs), and other mediators of inflammation. Consequences of an 
increased level of  these mediators of inflammation are the development of the 
cardinal symptoms of inflammation: redness, heat, swelling, pain, and loss of 
function.  IL-1, TNFα and IL-18 are initiators of this cascade of inflammatory 
mediators. These initiators are induced by infection, tissue damage, ischemia, 
immune-activated T cells, or toxins. For example the cytokines IL-12 and IL-18 are 
primarily secreted after microbial infection. This process leads to an induction of 
proinflamatory cytokines and IFNγ, which is known to direct T cell development  along 
a TH1 pathway.  Proinflammatory cytokines activate important regulators of gene 
transcription (e.g.: NF-κB, AP-1, NF-IL-6). Their overproduction is a frequent 
characteristic seen in human autoimmune diseases such as Crohn’s disease, lupus 
erythematosus, and rheumatoid arthritis.  
As mentioned above, there are antiinflammatory cytokines which are involved in 
controlling the proinflammatory cytokine response. The antiinflammatory cytokines 
are able to suppress genes coding for proinflammatory cytokines such as IL-1, TNF, 
and chemokines. In the presence of  IL4 and IL-10 activated naive T cells develop 
along the TH2 pathway. Secreted antiinflammatory binding proteins interfere with the 
action of proinflammatory cytokines on the level of bioactivity (Dinarello C.A., 
Moldawer L.L:, 2000). 
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1.1.3 Adaptive Immunity and the Role of T cell cytokines  
 
Infectious agents induce the very complex defense mechanism of  adaptive 
immunity. The type of immunity is developed out of a response to an infection and is 
individually adapted to a given specific kind of infection. Magnitude and defensive 
capabilities are increased with each successive exposure to a particular antigen.  
CD4
+ helper T cells respond to the protein antigens of microbes and may differentiate 
into special subsets of helper T cells called TH1 and TH2 cells. The differentiation into 
the various T helper cells is influenced primarily by the cytokines present during the 
initial proliferative phase of T-cell activation. This process not only determines the T 
cell effector function, but also the participation in the development and expansion of 
the respective subsets. For example, IFN-γ secreted by TH1 cells promotes further 
TH1 differentiation and inhibits the proliferation of TH2 cells in parallel. For cell-
mediated immune responses the most important differentiation-inducing stimuli are 
IFN-γ, IL-2, IL-12, and IL-18 being the major inducers of TH1 cells. TH1 differentiation 
is stimulated by intracellular bacteria, such as Listeria and mycobacteria, and by 
some parasites, such as Leishmania. These are all microorganisms  which can infect 
macrophages.  Many organ-specific autoimmune diseases and inflammatory 
reactions such as granulomas are due to excessive activation of TH1 responses. In 
contrast, TH2 development is promoted by stimulation of activated naive cells in the 
presence of IL-4 and IL-10. Both interleukins produced by TH2 cells inhibit activation 
of TH1 cells. So the most important differentiation-inducing stimuli for humoral 
responses are the cytokines IL-4 and IL-10 produced by TH2 cells.  TH2 differentiation 
occurs in response to helminth and allergens, which cause chronic T cell stimulation, 
often with little macrophage activation. The principal effector function of TH2 cells is in 
IgE and eosinophil/mast cell-mediated immune reactions. The balance between 
cytokine signals regulates the universal pattern of the aquired immune response. 
Once determined, the development into a TH1 or TH2 cell population amplifies itself 
and cross inhibits the other way. Chronic immune reactions  are often dominated by 
either TH1 or TH2 populations. T cell differentiation  is determined by stimuli present 
early during immune responses. The induction of IFN-γ is dominated by IL-12 and IL-
18, produced by accessory or antigen presenting cells such as macrophages or 
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dendritic cells, thereby linking acquired and innate immune responses.  (Janeway 
C.A. and Travers P., 1997; Dinarello C.A. and Moldawer L.L:, 2000). 
 
1.1.4 Interferon-γ 
Activated T cells and natural killer (NK) cells produce interferon-γ (IFN-γ), a 
pleiotropic cytokine involved in antiproliferative and antiviral responses, immune 
surveillance, and tumor suppression (Stark, G.R. et al, 1998; Bach E. et al, 1997). 
lFN-γ is the major means by which T cells activate macrophages. The complex 
genetic programs elicited by lFN-γ in the immune system, account for the diverse 
activities of IFN-γ in mediating host defense and immunopathology. Biological 
responses to IFN-γ are mediated mainly by regulation of gene expression. lt has 
been established that the majority of the pleiotropic effects of IFN-γ is owing to 
several gene products that are regulated by the Jak-Stat 1 (signal transducer and 
activator of transcription 1) pathway (Darnell J.E., Jr et al, 1994)   
 
1.1.4.1  IFN-γ and immunity 
 
IFN-γ is a homodimeric glycoprotein with pleiotropic immunologic functions in cell-
mediated immunity against intracellular microbes. IFN-γ can promote the microbicidal 
function of macrophages by stimulating the synthesis of reactive oxygen 
intermediates (ROI) and NO. These effects are mediated by activating transcription 
and/or assembly of the enzymes phagocyte oxidase and iNOS. These radicals serve 
to destroy microbes contained within phagolysosomes. IFN-γ enhances major 
histocompatibility complex class (MHC)-associated antigen presentation and 
amplifies the recognition phase of immune responses by increasing expression of 
ligands that are recognized by T cells. This cytokine also activates vascular 
endothelial cells and potentiates many of the actions of TNFα on endothelial cells, 
thereby promoting T lymphocyte adhesion and extravasation to sites of infection. The 
TH1 inducing effect of IFNγ is mediated indirectly by activating mononuclear 
phagocytes to produce IL-12, the prototype of TH1 cytokines. In mice IFN-γ also 
enhances expression of the signaling chain of the IL-12 receptor.  IFN-γ induces 
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antibody responses that also participate in phagocyte-mediated elimination of 
microbes. The B-cell IgG subclasses (IgG2a and IgG3) induced by IFN-γ bind to 
Fcγ receptors on phagocytes and activate complement. Both of these mechanisms 
promote the phagocytosis of opsonized microbes. Furthermore, IFN-γ activates 
neutrophils and enhances the cytotoxicity of NK cells (Janeway c.a. and Travers P., 
1997). The absence of IFN-γ production or cellular responsiveness in humans and 
experimental animals significantly predisposes the host to microbial infections.  Mice 
with a targeted disruption of the IFN-γ gene have been developed by homologous 
recombination in ES cells. These animals develop normally and are healthy in the 
absence of pathogens. They are characterized, however, by an impaired production 
of macrophage antimicrobial products and reduced expression of macrophage  MHC 
class II antigens. After infection, IFN-γ-deficient mice die by normally sublethal doses 
of the intracellular pathogen Mycobacterium bovis. Resting splenic natural killer cell 
activity is reduced in these mice (Dalton D.K., 1993). These observations validate the 
pathophysiological importance of this cytokine in preventing infectious diseases.                              
In addition to the aforementioned role of IFN-γ in immune defence against infection, 
IFN-γ has been characterized as a potent tumorsuppressive cytokine. The IFN-γ 
signaling pathway leads to apoptosis and to the expression of immune modulatory 
proteins (e.g. IP-10, MIG and iNOS) that can cooperate with T cells in the destruction 
of tumors. Various lines of experimental approach have, in general, supported the 
hypothesis that the IFN-γ signaling pathway is anti-tumorigenic (Ikeda H., et al, 
2002). In spite of the antiproliferative and tumorsuppressive activities of IFN-γ its use 
in the treatment of various malignancies has so far been disappointing. In many 
instances a combination treatment with other interferons, and also with 
chemotherapy was moderately effective only (Digel W et al 1991).  
 
1.2 Chemokines 
Chemokines are cytokines which can induce chemotactic reactions of cells. They are 
small proteins that are potent activators and chemoattractants for leukocyte 
subpopulations and some nonhematopoietic
 cells. Their actions are mediated by a 
family of seven transmembrane
 G protein-coupled receptors, the number of which 
has grown considerably
 in recent years. Significant advances
 have been made in 
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understanding the regulation of chemokine receptor
 expression and the intracellular 
signaling mechanisms used in
 bringing about cell activation. Chemokine receptors 
have also
 recently been implicated in several disease states including allergy,
 
psoriasis, rheumatoid arthritis, atherosclerosis, and malaria. However, most 
fascinating
 has been the observation that some of these receptors are used
 by 
human immunodeficiency virus type 1 in gaining entry into permissive
 cells (Murdoch 
C. and Finn A., 2000).  
   
Fig. 2: Chemokines and Leukocyte Movement. 
Chemokines are secreted at sites of inflammation and infection by resident tissue cells as well as, 
resident and recruited leukocytes. Chemokines are locally retained on matrix and cell-surface heparan 
sulfate proteoglycans. An established chemokine concentration gradient  is surrounding the 
inflammatory stimulus. Leukocytes rolling on the endothelium in a selectin-mediated process are 
brought into contact with chemokines recruiting cell-surface heparan sulfate proteoglycans. 
Chemokine signaling activates leukocyte integrins, leading to firm adherence and extravasation.  The 
Duffy antigen receptor for chemokines (DARC), a promiscous erythrocyte chemokine receptor, 
functions as a sink, removing chemokines from the circulation and thus helping establishing a tissue-
bloodstrearn chemokine gradient (adapted from Luster A.D., 1998). 
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Phagocytic leukocytes of the immune system undergo rapid and directed movements 
in chemoattractant gradients, a property that
 enables them to serve as the first line of 
cell-mediated host
 defense against infection. The interaction of chemoattractants
 with 
leukocytes initiates a series of coordinated biochemical
 and cellular events that 
include alterations in ion fluxes, integrin
 avidity as well as transmembrane potential, 
changes in cell shape, secretion
 of lysosomal enzymes, production of superoxide 
anions, and enhanced
 locomotion.                                                                              
Two groups of chemoattractants have been identified and extensively studied. The 
first group consists of "classical" chemoattractants, such as bacterial-derived
 N-
formyl peptides, the complement fragments C5a and C3a, and
 lipid molecules such 
as leukotriene B4 and platelet activating
 factor. These are all chemoattractants and 
activators of leukocytes (Schiffmann E. and Corcoran B.A., 1975; Gerard C. and 
Gerard N.P.,1994; Goldman D.W. and Goetzl E.J., 1982;  Hanahan D.J., 1986). The 
second group consists of  molecules which have been detected during the last 10 
years.  A number of chemotactic cytokines in the 8- to 17-kD
 molecular mass range 
have been shown to be selective chemoattractants
 for leukocyte subpopulations in 
vitro and to elicit the accumulation
 of inflammatory cells in vivo (Baggiolini M. et 
al,1994 and 1997). These chemotactic cytokines
 belong to the chemokine 
superfamily, which can be divided into
 4 groups (CXC, CX3C, CC, and C) according 
to the positioning of
 the first 2 closely paired and highly conserved cysteines in the
 
amino acid
 sequence. The specific effects of chemokines on their target cells are 
mediated by members of a family of seven transmembrane spanning
 G protein-
coupled receptors (Murphy PM.,1994). These chemokine receptors are
 part of a 
much larger superfamily of G-protein-coupled receptors
 that include receptors for 
hormones, neurotransmitters, paracrine
 substances, inflammatory mediators, 
proteinases, taste
 and odorant molecules, and even photons and calcium ions 
(Watson B., 1994).  
Fig. 3: Chemokines and their Detectors                                                                                                  
The chemokines are  8-to-10-kD proteins that are subdivided into families on the basis of the relative 
position of conserved cysteine residues in the mature protein. In the α-chemokines, the first two 
cysteine residues are separated by a single amino acid (CXC), whereas in the β-chemokines, these 
two cysteine residues are adjacent to each other (CC). The α-chemokines that contain the sequence 
glutamic acid-leucine-arginine preceding the CXC sequence are chemotactic for neutrophils, and 
those that do not contain this sequence act on lymphocytes. The C chemokine lymphotactin has only 
two cysteines in the mature protein, and the CXXXC chemokine fractalkine has three amino acids 
separating the first two cysteines. Chemokine receptors are G protein-coupled proteins that are 
expressed on subgroups of leukocytes. Four human CXC chemokine receptors (CXCR1 through 
CXCR4), eight human CC chemokine receptors (CCR1 through CCR8), and one human CXXXC 
chemokine receptor (CX3CR1) have been identified so far. MCP denotes monocyte chemoattractant 
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protein, MIP macrophage inflammatory protein, RANTES regulated upon activation normal T-cell 
expressed and secreted, MDC macrophage-derived chemokine, HCC-1 hemofiltrate CC chemokine, 
TECK thymus-expressed chemokine, SDF-1 stromal-cell-derived factor 1, TARC thymus and 
activation-regulated chemokine, ELC EBI1 (Epstein-Barr virus-induced gene 1) ligand chemokine, 
PARC pulmonary and activation-regulated chemokine, SLC secondary lymphoid tissue chemokine, 
6Ckine 6-cysteine chemokine, IP-10 interferon-inducible protein l0, MIG monokine induced by 
interferon-γ, I-TAC interferon-inducible T-cell alpha chemoattractant, DC-CK1 dendritic-cell chemokine 
1, LARC liver and activation-regulated chemokine, GCP granulocyte chemotactic protein, GRO 
growth-regulated oncogene, ENA-78 epithelial-cell-derived neutrophil-activating peptide 78, NAP-2 
neutrophil-activating peptide 2, and LIX lipopolysaccharide-induced CXC chemokine (adapted from 
Luster, A.D., (1998)). 
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1.2.1 Chemokines in Cancer      
Chemokines modulate tumor behaviour by three main mechanisms: regulation of 
tumor-associated angiogenesis, activation of the host’s tumor-specific immunological 
response, and direct stimulation of tumor cell proliferation in an autocrine fashion. All 
of these mechanisms are promising targets of cancer intervention, and preclinical 
mouse models suggest that certain chemokine antagonists and agonists could 
become important in the development of new anticancer therapies (Belperio J.A., et 
al. 2000). 
 
1.2.1.1 Chemokines modulate angiogenesis  
Angiogenesis is the growth of new blood vessels from already existing vessels and 
microcapillaries (Norrby K., 1997). It is a process that normally takes place during 
embryonic development and wound healing, but is also required for solid tumors to 
grow beyond 2 mm in diameter (Norrby K., 1997; Folkman J., 1995). Vascularisation 
of a tumor is required for rapid growth ( Folkman J., 1995).  
 
1.2.1.1.1 Imbalance of chemokines modulating angiogenesis regulates tumor 
growth 
The Far Eastern concept of ‘Yin and Yang’ (i.e. that everything is controlled by two 
equal but opposing forces) is a recurring motif throughout biology, as processes such 
as angiogenesis must be temporally turned on and off during the life of an organism. 
It has been proposed that angiogenesis is regulated by a complex balancing act 
between opposing angiogenic and angiostatic factors (Moore B.B., et al, 1998). 
Considerable experimental evidence suggests that this hypothesis is valid. Much of 
the data are supporting a role for CXC chemokines in modulating the angiogenesis of 
tumors in vivo (Belperio J.A. et al, 2000).  For example the participation of IL-8 in 
macrophage-mediated angiogenesis is suggested by the observation that IL-8 
antisense RNA blocks monocyte-induced angiogenic activity (Koch A.E., et al, 1992). 
In contrast to the proangiogenic IL-8, the chemokines IP-10 and MIG are potent 
antiangiogenic mediators. Tumor cells genetically engineered to express high levels 
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of murine IP-10 have been shown to elicit a powerful host-mediated antitumor effect 
in vivo which appears to be mediated by the recruitment of inflammatory infiltrates 
composed of lymphocytes, neutrophils, and monocytes. Notably, IP-10 has been 
shown to be a potent endogenous inhibitor of angiogenesis (Angiolillo A.L., et al, 
1995). Moreover, injection of recombinant human MIG into Burkitt tumors growing 
subcutaneously in nude mice causes tumor necrosis associated with extensive 
vascular damage (Sgadari et al, 1997). Finally, high levels of MIG and IP-10 gene 
expression were reported in tissues with necrosis and vascular damage in EBV 
positive lymphomatoid granulomatosis and nasal-type T/natural killer cell lymphomas 
(Teruya-Feldstein et al, 1997). The following table shows chemokines that modulate 
angiogenesis: 
Figure 4 
Angiostatic
Chemokines
PF4
IP-10
MIG
I-TAC
SDF-1
MIP-2γ
Angiogenic
Chemokines
GRO-α
GRO-β
GRO-γ
ENA-78
GCP-2
NAP-2
IL-8
 
 
1.2.1.2 Chemokines can activate tumor-specific immunity 
One of the greatest challenges in developing tumor vaccines is getting the host to 
recognize tumors that might be poorly immunogenic for a number of reasons. There 
is considerable experimental evidence that certain chemokines, particularly those 
from the CC family, are able to activate a tumor-specific immune response capable of 
mediating rejection of ordinarily ‘non-immunogenic’ cancers. These are for example 
MIP-1α, ELC, LARC and SLC (Mitchell J., et al, 2001). This is particularly significant, 
as one of the major obstacles in using immunotherapy to treat cancer has been the 
low immunogenicity of spontaneously arising human tumors (Bodey B., et al, 2000). 
Certain members of the CC chemokine family are chemotactic for either monocytes 
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and dendritic cells (antigen-presenting cells) or T cells (including cytotoxic T cells, 
and T helper 1 cells). These cell types are of major importance in generating specific 
immunity. An example demonstrating that chemokines can activate tumor-specific 
immunity are experiments with mice that are able to reject a colon adenocarcinoma 
cell line only if it has been engineered to express macrophage inflammatory protein 
1α (MIP-1α/CCL3). This chemokine is chemotactic for monocytes, T cells and 
dendritic cells (Nakashima E., et al, 1996). Mice that had successfully rejected the 
MIP-1α transfected tumor cells are protected from subsequent inoculation with the 
parental unmodified adenocarcinoma cells. The rejected tumors are highly infiltrated 
by macrophages and neutrophils. Immune modulatory factors produced in the 
microenvironment within a tumor can determine whether or not an immune response 
will take place. Chemokines can influence  production of these factors by recruiting 
and activating cytotoxic T cells and NK cells.  
 
1.2.2 Chemokines as autocrine growth factors 
Autocrine growth factors are proteins that can bind to receptors on the same cell that 
also produce them and that can stimulate cell proliferation. The GRO CXC 
chemokines were originally called ‘melanoma growth stimulatory activity’ 
polypeptides because these proteins are mitogenic for malignant melanoma cell lines 
in vitro. GRO-α was initially isolated from conditioned supernatant of the melanoma 
cell line Hs294T (Richmond A., et al, 1988), and is now known to be produced by 
many melanoma tumors. The significance of GRO chemokine expression in 
melanoma has been examined (Luan J., et al, 1997). Both GRO-α and its receptor 
CXCR2 are commonly expressed in malignant melanoma biopsies as assessed by 
immunohistochemistry. GRO-α and GRO-γ are expressed by melanoma tumors in 
vivo, but expression of the alpha form tends to be higher. As antibodies to GRO-α 
were found to inhibit in vitro growth of melanoma cell lines, GRO-α fits all the criteria 
for an autocrine growth factor. GRO-α has also been shown to function as an 
autocrine growth factor for certain adenocarcinoma cell lines derived from lung and 
stomach (Fujisawa N., et al, 2000).                                                                   
Many tumors have been shown to overexpress IL-8, compared with their normal, 
non-malignant tissues. IL-8 is an autocrine growth factor for melanomas 
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(Schadendorf D., et al, 1993) as well as for certain tumor cells derived from cancers 
of the colon, stomach, liver, pancreas and skin (Fujisawa N., et al, 2000; Brew R., et 
al. 2000; Miyamoto M., et al, 1998; Metzner B., et al, 1999). In human biopsy tissues 
from ovarian carcinomas, neuroblastomas, and squamous cell carcinomas of the 
head and neck, both IL-8 and its receptor are expressed by cancerous cells, 
suggesting that IL-8 may also function in an autocrine loop in these tumors (Ivarsson 
K., et al, 2000; Ferrer F.A., et al, 2000; Richards B.L., et al, 1997). The autocrine 
functions of GRO-α and IL-8 illustrate the pleiotropism of chemokines, as these 
particular molecules not only stimulate tumors to multiply, but also recruit and expand 
endothelial cells in vivo to ensure that tumors develop an adequate vasculature as 
they grow. Thus, GRO-α and IL-8 are  the most ideal tumor growth factors. 
 
1.3 Nitric Oxide (NO) 
NO is an important signaling molecule that acts in many tissues to regulate a diverse 
range of physiological processes including vasodilation , neuronal function, 
inflammation and immune function. Its role was first discovered by several groups 
who were attempting to identify the agent responsible for promoting blood vessel 
relaxation and regulating vascular tone. This activity was termed endothelium-derived 
relaxing factor (EDRF). The discovery that EDRF was in fact nitric oxide - a small 
gaseous molecule - has led to an explosion of interest in this field. Nitric oxide has 
now been demonstrated to play a role in a variety of biological processes including 
neurotransmission, immune defence, and regulation of apoptotic cell death. Nitric 
oxide is a fairly short-lived molecule (with a half-life of a few seconds) produced by 
enzymes known as nitric oxide synthases (NOS). NO diffuses rapidly across cell 
membranes and, depending on the conditions, is able to cover a distance of several 
hundred microns. The biological effects of NO are mediated through the reaction of 
NO with a number of targets such as haem groups, sulfhydryl groups and iron and 
zinc clusters. Such a diverse range of potential targets for NO explains the large 
number of systems that utilize it as a regulatory molecule. Accordingly, abnormal 
regulation of NO synthesis is capable of affecting a number of important biological 
processes and has been implicated in a variety of diseases (Kolb J.P., 2000). 
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1.3.1 Nitric Oxide Synthases (NOS)
NO is produced by a group of enzymes called nitric oxide synthases. These enzymes 
convert arginine and O2 into citrulline and NO. NADPH is a necessary co-factor. 
There are three isoforms of nitric oxide synthase (NOS) named according to the 
tissue type in which they were first described. The isoforms of NOS are neuronal 
NOS (or nNOS), endothelial NOS (or eNOS) and inducible NOS (or iNOS). All three 
isoforms can be found in a variety of tissues and cell types. The general path of NO 
production by NOS is illustrated in Figure 5: 
Figure 5:
 
Two of the enzymes (nNOS and eNOS) are constitutively expressed in mammalian 
cells and synthesize NO in response to increases in intracellular calcium levels. 
Activation of iNOS activity is not directly mediated by Ca
2+, but is rather regulated on 
the level of gene transcription. Like all of the NOS isoforms – iNOS activation is 
dependent on the binding of calmodulin (CaM). In case of iNOS, CaM is irreversibly 
bound to the enzyme and the activity of the enzyme is regulated by its rate of 
expression rather than by the Ca 2+ concentration. In the absence of CaM iNOS is 
highly unstable. The signalling cascade for Ca
2+-dependent eNOS/nNOS activation is 
initiated by ligand-induced activation of phospholipase C, which results in the 
formation of inositol (1,4,5)-trisphosphate, and the release of Ca
2+ from inositol 
(1,4,5)-trisphosphate-sensitive intracellular Ca
 2+ stores. In the course of store 
depletion, store-operated Ca
2+ channels are activated, resulting in a Ca
2+ influx, 
referred to as capacitative Ca
2+ entry. Both, release and influx of Ca
2+ lead to a 
transient increase in [Ca
2+]i. Ca
2+  then binds to CaM and the Ca
2+/CaM complex 
associates with eNOS/nNOS leading to enzyme activation (Mayer, B. and Hemmens, 
B. 1997). By contrast iNOS is able to bind tightly to calmodulin even at very low 
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cellular concentration of calcium, and once synthetized it is active. The production of 
NO by iNOS is primarily controlled by transcriptional mechanisms. In most 
unstimulated cell types iNOS protein levels are either very low or undetectable. The 
most characteristic feature of iNOS is its  prominent activation by proinflammatory 
cytokines (e.g. IFNγ and TNFα) or inhibition by antiinflammatory cytokines (e.g. IL-4, 
IL-10, IL-13 and transforming growth factor β (TGF−β). (Mac Micking J. et al (1997); 
Beck C. et al. (1999); Bogdan C. et al (2000). 
   
1.3.2 Pathophysiological Roles of NO
Since the discovery that NO is able to induce vasodilation, a large number of other 
roles have been described for this messenger. NO has also been implicated in the 
control of vascular permeability and blood vessel formation (angiogenesis). It is also 
known to play a role in the immune system, the nervous system, in inflammation and 
in programmed cell death (Jaiswal M., et al. 2001). 
 
1.3.3 Role in  immune defense 
NO can be produced by a number of cell types involved in local immune responses. 
In particular cytokine-activated macrophages can produce high concentrations of NO 
in order to kill target cells. NO-mediated cytotoxicity is often associated with the 
formation of nitrosyl thiol complexes in enzymes within the target cell. Killing by NO 
may also involve disruption of enzymes of the Kreb's cycle, reduced DNA synthesis, 
impaired mitochondrial function and induction of apoptosis. ( Brüne et al. (1998); 
Bogdan C., et al, (2000)) 
 
1.3.3.1 Cellular responses mediated by NO 
The effects of NO on cellular factors are generally classified as cGMP dependent or 
independent. Nitric oxide is able to activate cGMP signaling through the interaction of 
NO with the haem group of guanylate cyclase (Ignarro, 1990). The production of 
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cGMP leads to the activation of cGMP-dependent protein kinases and possibly to 
increased expression of cGMP-related genes (Beck C. et al. (1999); Pfeilschifter J. et 
al. (2001)). Another way by which NO activates cells is via protein kinase cascades. 
This was first reported by Lander et al. (1993). They report that, in human peripheral 
blood mononuclear cells, NO generating compounds stimulated a membrane-
associated protein tyrosine phosphatase activity which led to a dephosphorylation 
and activation of the src family protein tyrosine kinase p56
lck which is critically 
involved in T cell activation. Later it was shown that NO activates all three mitogen-
activated protein kinase (MAPK) cascades in Jurkat T cells, i.e. the stress-activated 
protein kinase/c-Jun N-terminal kinase (SAPK/JNK) cascade, the stress-activated 
p38 MAPK cascade and the classical ERK/MAPK cascade (Lander et al., (1996); 
Pfeilschifter J. and Huwiler A. (1996); Huwiler A. and, Pfeilschifter J.(1999); Mühl H,et 
al. (1999)). Other possible targets for NO are represented  the family of protein 
phosphatases. By direct interaction with this class of enzymes, either an activation or 
inhibition of phosphatase activity may be achieved, and this will lead to increased or 
decreased phosphorylation of their target proteins which include, importantly, 
members of the different MAPK pathways. Activation of a membrane-bound 
phosphatase was reported in T cells (Lander et al., (1993); for review see: 
Pfeilschifter et al. (2001)). 
 
1.4 Transcription factors  
 
 
The generation of the more than 200 different specialized cell types of the 
mammalian organism requires the establishment of diverse gene expression patterns 
that characterize the individual cell types.These patterns are formed through the 
combinatorial action of transcriptional regulatory proteins, some of which 
have the capacity to direct multipotent cells to assume a specific developmental fate. 
Transcription factors are proteins that bind to DNA near the start of transcription of a 
gene. These proteins either inhibit or assist RNA polymerase in initiation and 
maintenance of transcription. 
 
 
 
 
16                                                                                                                    Introduction 
1.4.1 NFκB 
 
Nuclear factor kappa B (NF-κB) is a protein transcription factor that is required for 
maximal transcription of a wide array of proinflammatory molecules which are 
thought to be important in the generation of acute inflammation. 
Members of the NF-κB family of transcription factors are expressed in most cell types 
of vertebrates. Five structurally related Rel/NF-κB proteins are known and can be 
detected as homo- and heterodimers (Baldwin, A. S., jr. 1996; Ghosh, S., et al. 
1998). In nonstimulated cells NF-κB is sequestered in the cytoplasm in an inactive 
form via interaction with inhibitory proteins, the inhibitors of NF-κB (IκB) (Baeuerle 
P.A., and Baltimore D., 1988). The three most important IκBs are: IκBα IκBβ, and 
IκBε (Davis N., et al, 1991; Haskill S., et al, 1991; Thompson J.E., et al, 1995; 
Whiteside S.T., et al, 1997), bind the Rel homology domain (RHD) of NF-κB dimers 
und mask their nuclear localization signal (NLS)(Beg, A.A. et al. 1992; Ganchi, P.A., 
et al. 1992; Hatada, E.N.,et al. 1992;Zabel, U. et al.. 1993). Upon stimulation with 
various activators such as bacterial products, proinflammatory cytokines, viral 
proteins, and radiation, IκBs are rapidly phosphorylated at two serines located in their 
NH2-terminal regulatory region. Thereafter, they are ubiquitinated, and degraded by a 
proteasome dependent mechanism (Nanterniet, and A.S. Baldwin, Jr. 1993; Henkel, 
T., et al. 1993). The exposure of the NLS results in a rapid nuclear translocation of 
NF-κB, which then binds decanucleotide sequences in responsive promotors. This 
process activates transcription of several genes. Among them are proinflammatory 
chemokines and cytokines, adhesion molecules, and antiapoptotic or cytoprotective 
genes (Ghosh, S., et al. 1998; Mayo, M.W., and A.S. Baldwin. 2000). IκB itself is a 
NF-κB inducible gene. After induction IκBα enters the nucleus, enhances NF-κB 
removal from DNA (Zabel, U., and P.A. Baeuerle. 1990), and takes NF-κB back to 
the cytoplasm, thus restoring the inducible cytoplasmic pool of the transcription factor 
(Arenzana-Seisdedos, F., et al 1995).                                                                        
Lipopolysaccharide (LPS) stimulated recruitment of NF-κB to target genes in  
macrophages occurs in two temporally distinct phases. A subset of target genes 
whose promoter is already heavily acetylated before stimulation is immediately 
accessible to NF-κB and initiation of transcription occurrs fast. In contrast, other 
target genes are not immediately accessible to NF-κB.  
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The state of acetylation of DNA representing an ORF (open reading frame) is an 
indicator for its activity. Inactive DNA is  wound up on histon-protein-comlexes which 
loose their affinity to DNA by acetylation.  Acetylation of DNA actually means that the 
histon complexes get acetylated, loose their affinity to DNA and the DNA is 
transformed into its stretched form in which it can be transcribed more easily.    
Recruitment of NF-κB to sensitive promotors occurs within 120 min after nuclear 
entry and is preceeded by the formation of an initial transcription factor complex that 
directs the hyperacetylation of the promoter and makes it accessible to NF-κB. The 
dependency on modifications in chromatin structure for activation by NF-κB in certain 
genes is a mechanism allowing a highly selective regulation of these promotors in 
response to NF-κB (Simona S., et al, 2001).             
In RAW macrophages and human peripheral blood mononuclear cells (PBMC) 
treatment with NO donors such as sodium nitroprusside (SNP), S-nitroso-N-
acetylpenicillamine (SNAP) and GSNO resulted in enhanced binding activity of NF-
κB family members (Lander et al., 1993; Knethen A., et al. 1999). In other cell types 
like in vascular endothelial cells activation of NF-κB binding following cytokine 
treatment can be inhibited by treatment with NO donors (Peng, et al, 1995). NO is a 
molecule with both anti-oxidant and pro-oxidant properties depending on the 
availability and concentration of potential reaction partners such as superoxide and 
hydrogen peroxide or other reactive oxygen species (ROS). This may explain the 
disparate observations in some cells (Pfeilschifter et al. 2001). Peroxinitrite (ONOO-) 
induces in a dose dependent manner the release of proinflammatory cytokines in 
human monocytes through activation of NF-κB DNA binding activity (Matata and 
Galinanes 2002).     
 
 
1.4.2 AP-1 
 
Activator protein-1 (AP-1) is an inducible transcription factor of the bZip family and is 
critical for the expression of many genes involved in the inflammatory response, 
including cytokines and adhesion molecules. Binding of TNF-α to its cell surface 
receptor activates AP-1 through a cascade of kinases that include a MAP kinase 
kinase kinase (MEKK1), a MAP kinase kinase (MKK4 and MKK7), and a MAP kinase 
[JNK (c-Jun N-terminal kinase)] (Yoshimura T., et al, 1987; Larsen C.G., et al, 1989). 
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AP-1 is composed of either Jun-Fos heterodimers or Jun-Jun homodimers (Smeal T., 
et al. 1989). AP1 binding sites can also interact with transcription factors of the 
CREB/ATF family by forming heterodimers with Jun and Fos proteins (Matthews J.R., 
et al, 1996; Rabbi M.F., et al.,1997).  AP- 1 activity is controlled at both, 
transcriptional and posttranscriptional levels. Regulation at the posttranscriptional 
level is mediated by the state of protein phosphorylation. AP-1 transcriptional activity 
is dependent on the phosphorylation of two serine residues in the transactivation 
domain of Jun (Paine, R.D., etal., 1993). In addition AP1 binding activity is controlled 
by dephosphorylation of specific serine and threonine residues in the DNA binding 
domain of Jun (Standiford T.J., et al., 1991).  In terms of transcriptional regulation, 
the c-fos promotor is rapidly activated (within 30min) in response to a variety of 
external signals, which lead to increased production of cFos protein and, when 
combined with a member of the Jun family, increased AP-1 biological activity (Karin, 
M., et al., 1997). AP-1 can be directly modificated by NO in vitro. The major 
components of AP-1 wich are c-Fos and c-Jun have single conserved cysteine 
residues within the DNA binding domains. These cysteine residues seem to be 
responsible for redox regulation of AP-1 activity. Nitrosylation of critical cysteines 
lead to the inhibition of AP-1 activity, suggesting that NO mediates regulation of the 
AP-1 transcription factor (Tabuchi et al., 1994).  
 
1.4.3 Modulation of gene expression by NO 
During the last years, an increasing number of genes have been shown to be under 
regulatory control by nitric oxide, including growth factors (Sasaki, et al, 1998; 
Tsurumi, et al., 1997; Chin, et al., 1997), cytokines (VanDervort, et al., 1994), 
chemokines (Villarete and Rernick, 1995; Mühl and Dinarello, 1997), receptors 
(Ichiki, et al., 1998) or enzymes (Hartsfield et al, 1997; Mühl and Pfeilschifter, 1995; 
for review see: Pfeilschifter et al. 2001). The gene for interleukin-8 (IL-8) has been 
show to be under transcriptional control by NO. In human endothelial cells, TNF-α-
stimulated IL-8 production was inhibited by the NOS inhibitor (L)-N
G-nitroarginine 
methylester (L-NAME) in a dose-dependent manner. Moreover, exogenously added 
NO donors induced IL-8 expression (Villarete and Remick, 1995). Besides IL-8, TNF-
α appears to be induced in a paracrine manner by endothelial and smooth-muscle-
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derived NO in human neutrophils (VanDervort et al., 1994). Moreover, in human T 
lymphocytes NO mediated an increase in mRNA levels of TNF-α, which was ERK 
dependent (Deora A.A., et al, 2000).  Furthermore, expression of macrophage 
inflammatory protein 1α (MIP-1α), another member of the chemokine family, was 
directly dependent on LPS-induced NO synthesis in PBMC (Mühl H. and Dinarello 
C., 1997), a process that may be initiated by PKB mediated activation of eNOS in 
human monocytic cells.         
Vascular endothelial growth factor (VEGF), a growth factor mediating angiogenesis 
and vascular permeability, was found to be induced by NO in human glioblastoma 
and hepatocellular carcinoma cells. For both cell types, NO induced gene expression 
is mediated through the activation of, guanylate cyclase (Chin K. et al, 1997).  In 
contrast, in mesangial cells NO-evoked expression of VEGF was independent of 
cGMP. Noteworthy, the regulation of the VEGF receptor Flt-1 was found to be 
regulated in NO/cGMP-dependent manner in mesangial cells (Frank et al.1999).                              
Finally, NO is even able to trigger transcription of its own biosynthetic machinery: NO 
was found to increase IL-1β-induced iNOS gene expression at the transcriptional 
level in mesangial cells and vascular smooth muscle cells. Inhibition of NO synthesis 
clearly reduced IL1β-stimulated iNOS expression, suggesting that NO functions in a 
positive feedback loop that speeds up and strengthens its own biosynthesis (Mühl 
and Pfeilschifter, 1995; Boese M., et al.1996). 
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2 Materials and Methods 
___________________________________ 
 
2.1 Materials 
 
2.1.1 Chemicals 
 
Acrylamide/bisacrylamide-solutions Roth,  Karlsruhe 
Agar  Gibco Life Technologies, Eggenstein 
Agarose Biozym,  Oldendorf 
Ammoniumpersulfate Sigma  Biochemicals, Deisenhofen 
Ampicillin Sigma  Biochemicals, Deisenhofen 
Aprotinin  Roche Biochemicals, Mannheim 
[γ-
32P]ATP  Amersham Pharmacia, Braunschweig 
Bovine serum  albumin  Sigma Biochemicals,Deisenhofen 
Gibco Life Technologies, Eggenstein 
5-Bromo-4-chloro-3-indolyl-β-D-
galactoside 
Roth, Karlsruhe 
Cell culture media  Gibco Life Technologies, Eggenstein 
Complete (protease inhibitor)  Roche Biochemicals, Mannheim 
[α-
32P]dCTP  Amersham Pharmacia, Braunschweig 
DETA-NONOate Alexis,  Grünberg 
Diethylpyrocarbonate  Sigma Biochemicals, Deisenhofen 
Dithiothreitol Sigma  Biochemicals, Deisenhofen 
Ethidium bromide  Sigma Biochemicals, Deisenhofen 
Ficoll  Sigma Biochemicals, Deisenhofen 
Fugene 6  Roche Biochemicals, Mannheim 
Glutathione  Sigma Biochemicals, Deisenhofen 
Guanidinium thiocyanate  Sigma Biochemicals, Deisenhofen 
Hydroxylammoniumchloride Merck,  Darmstadt 
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8-Hydroxyquinoline Sigma  Biochemicals, Deisenhofen 
IL-1β  Cell Concepts (Umkirch, Germany) 
Isopropylthiogalactoside Roth,  Karlsruhe 
Leupeptin  Roche Biochemicals, Mannheim 
Lipopolysaccharide Sigma  Biochemicals, Deisenhofen 
L-N
6-(1-iminoethyl)lysine Alexis,  Grünberg 
β-Mercaptoethanol  Sigma Biochemicals, Deisenhofen 
Molecular weight markers (DNA)  MBI Fermentas, St. Leon-Rot 
Molecular weight markers (protein)  Amersham Pharmacia, Braunschweig 
N
G-monomethyl-L-arginine Alexis,  Grünberg 
N-naphtylethylendiamine 
dihydrochloride 
Sigma Biochemicals, Deisenhofen 
Nucleotide triphosphates  PE Biosystems, Weiterstadt 
Oligonucleotides Roth,  Karlsruhe; Gibco Life Technologies, 
Eggenstein; MWG, Ebersberg 
Pepstatin  Roche Biochemicals, Mannheim 
Peptone  Gibco Life Technologies, Eggenstein 
Phenol/Chloroform Roth,  Karlsruhe 
Ponceau S  Sigma (Deisenhofen, Germany) 
Polymyxin B (PmxB)   Sigma (Deisenhofen, Germany) 
Pyrrolidine  dithiocarbamate  Calbiochem-Novabiochem GmbH (Bad 
Soden, Germany) 
RNasin   Promega, Mannheim 
Rothi Load   Roth, Karlsruhe 
Skim milk (non fat)  Fluka, Deisenhofen 
Sodium nitroprusside  Sigma Biochemicals, Deisenhofen 
Sodiumlaurylsarcosyl Serva,  Heidelberg 
Triton X-100  Sigma Biochemicals, Deisenhofen 
Tumor necrosis factor α (TNFα)  Knoll AG (Ludwigshafen, Germany) 
tRNA, RNase free  Roche Biochemicals, Mannheim 
Trypan blue  Gibco Life Technologies, Eggenstein 
Tween 20  Sigma Biochemicals, Deisenhofen 
[α-
32P]UTP  Amersham Pharmacia, Braunschweig 
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Yeast extract  Gibco Life Technologies, Eggenstein 
Zeocin  InVitrogen, Groningen, Netherlands 
 
Acetone, organic and inorganic acids, chloroform, ethanol, ether, methanol and 
isopropanol were from the supply store of the Universitätsklinikum Frankfurt. All 
other, not listed chemicals were purchased either from Merck (Darmstadt), or Roth 
(Karlsruhe) or Sigma Biochemicals (Deisenhofen). 
 
2.1.1.1 S-nitroso-glutathione 
 
Glutathione was dissolved in 0.625 N HCl on ice to a final concentration of 625 mM. 
NaNO2 was added in an equimolar amount and the mixture was stirred at 0°C for 
40 min. After the addition of 2.5 volumes of acetone stirring went on for additional 
20 min, followed by filtration of the precipitate. GSNO was washed once with 80% 
acetone, two times with 100% acetone, and finally three times with diethylether and 
dried under vacuum. The powder was aliquoted in Eppendorf tubes and stored at –
20°C until use. 
 
2.1.2 Enzymes 
 
Alkaline shrimps phosphatase  Roche Biochemicals, Mannheim 
DNA polymerase T4  MBI-Fermentas, St. Leon-Rot 
Pfu-DNA polymerase   Stratagene, Heidelberg 
Turbo Pfu-DNA polymerase   Stratagene, Heidelberg 
Proteinase K  Roche Biochemicals, Mannheim 
Restriction enzymes 
 
Roche Biochemicals, Mannheim; 
Stratagene, Heidelberg; 
MBI-Fermentas, St. Leon-Rot; NEB 
Reverse transcriptase  Roche Biochemicals, Mannheim 
RNA polymerase T3 and T7  Roche Biochemicals, Mannheim 
RNase A and T1  Roche Biochemicals, Mannheim 
T4-DNA ligase  Roche Biochemicals, Mannheim 
Taq-DNA polymerase  PE Biosystems, Weiterstadt 
TaqGold-DNA polymerase  PE Biosystems, Weiterstadt 
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2.1.2.1 Pretreatment of enzymes  
 
2.1.2.1.1 Proteinase K 
The lyophilized enzyme was dissolved in Aqua dest. (10 mg/ml), incubated for 30 
min at 37°C and aliquoted. The aliquots were stored at –20°C until use. 
 
2.1.2.1.2 RNase A 
RNase A was dissolved to a final concentration of 10 mg/ml in RNase-buffer 
[Tris/HCl (10 mM, pH 7.5), NaCl (15 mM)]. The enzyme solution was incubated for 
30 min at 95°C and cooled to room temperature over night. Aliquots were stored at 
–20°C until use. 
 
 
2.1.3 Kits 
 
Dnazol Stratagene,  Heidelberg 
Cell Death Detedtion Elisa Roche  Biochemicals 
ECL Detection Kit  Amersham Pharmacia, Freiburg 
ECL Films   Amersham Pharmacia, Freiburg 
Quick Spin Purification Kit   Machery &Nagel, Düren 
Quick Change Site-Directed 
Mutagenesis Kit 
Stratagene, Heidelberg 
Promega Luciferase Assay System Promega,  Madison 
Nanoquant Roth,  Karlsruhe 
LDH- Assay  Boehriner Mannheim, Mannheim 
Germany 
Rediprime Labelling Mix (RPN1633)  Amersham Pharmacia Biotech, Freiburg 
Germany  
Midi-/Maxi-Kits for Plasmid purification  Quiagen, Hilden and Machery & Nagel, 
Düren both Germany 
Optia Elisa Kits for IP-10 and IL-8 
detection 
Pharmingen 
TOPO TA Cloning  Invitrogen, Groningen (Netherlands) 
Trizol  Sigma Biochemicals, Deisenhofen  
  24Materials and Methods 
 
VEGF Elisa  R&D Systems, Nordenstadt (Germany) 
 
 
2.1.4 Laboratory equipment 
 
ABI-Prism 310 Genetic Analyser  Perkin Elmer Biosysterns, 
 
Weiterstadt 
Gel dryer 583  Bio-Rad, München 
GeneAmp 2400/9600 Thermocycler  Perkin Elmer Biosysterns, 
 
Weiterstadt 
Gene Quant II  Amersham Pharmacia, 
 
Braunschweig 
Herasafe clean bench  Heraeus, Hanau 
Hyperprocessor Amersham  Pharmacia, 
Incubator Heraeus BBD 6220  Heraeus, Hanau 
Megafuge Haraeus 1.0 (rotor 7570F)  Heraeus, Hanau 
Microplate reader Benchmark  Bio-Rad, München 
Phospholmager BAS 1500  Raytest, Straubenhardt 
Trans-Blot SD  Bio-Rad, München 
TRI-CARB 2100 TR ß-counter  Canberra-Packard, Dreieich 
Luminometer Berthold 
 
2.1.5 Antibodies and antisera 
Anti-rabbit IgG (horseradish-
peroxidase coupled) 
Bio-Rad, Munich, Germany 
Anti-human HO-1 (rabbit, polyclonal)  Stressgene, Hamburg, Germany 
Anti-human iNOS 
(mouse,monoclonal) 
Pharmingen 
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2.1.6 Recombinant and purified proteins 
 
IFN-γ (human)  PeproTech, Frankfurt 
IFN-γ (murine)  Roche Biochemicals, Mannheim 
IL-1β  Cell Concepts (Umkirch,Germany) 
TNF-α  Knoll AG (Ludwigshafen, Germany) 
 
 
2.1.7 Plasmids 
 
2.1.7.1 Vectors 
 
pBluescript II KS (+)  Stratagene, Heidelberg 
pGL3-Basic vector luc Promega,  Mannheim 
pCMV-galactosidase Stratagene,  Heidelberg 
TOPO II  Stratagene, Heidelberg 
 
2.1.7.2 Recombinant plasmids 
 
pGL3 Luc(+) IL8 wild 
(Human,nucleotides -558- +98bp) 
 
pGL3 Luc(+) IL8 AP-1 
(human,nucleotides -558- +98bp) 
Vlahopoulos et al. 1999 
pGL3 Luc(+) IL8 C/EBPβ 
(human,nucleotides -558- +98bp) 
Vlahopoulos et al. 1999 
pGL3 Luc(+) IL8 NF-κB 
(human,nucleotides -558- +98bp) 
Vlahopoulos et al. 1999 
pBKS(+)GAPDHb       
(human, nucleotides 148-302) 
Tokunaga et al. 1987 
pBKS(+)hIL-8 (human, nucleotides 
146-433) 
Matsushima et al,1988 
pBKS(+)HO-1    
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(human, nucleotides 706-949) 
pBKS(+)iNOS (human)  kindly provided by Dr. H. Kleinert, Mainz 
pBKS(+)VEGF (human, nucleotides 
339-498) 
Weindel et al. 1992 
TOPO II(+)IP-10 (human,  nucleotides 
115-403) 
  
TOPO II(+)MIG (human,  nucleotides 
81-401) 
 
 
 
2.1.8 Bacterial strains 
 
    Genotype 
E.coli DH5α  Gibco Life Technologies, 
Eggenstein 
supE44 ∆lac U169 
(∅80lacZ∆M15) hsd R17 recA 
endA1 gyrA96 thi-1 relA1 
E.coli XL-1 
blue 
Stratagene, Heidelberg  supE44 hsdR17 recA1 endA1 
gyrA46thi relA1 lac- F`[proAB+ 
lacIq lacZ∆M15 Tn10(tetr)]   
TOP10 Invitrogen,  Groningen 
(Netherlands) 
F
- mcrA ∆(mrr-hsdRMS-
mcrBC)Φ80lacZ ∆M15 ∆lacX74 
recA1 deoR araD139 
∆(araleu)7697 galU galK rpsL 
(Str
R) endA nupG 
 
 
2.1.9 Eukaryotic cell lines 
 
DLD-1 cells 
Human colon carcinoma cells 
Centre for Applied Microbiology & 
Research (Salisbury, United Kingdom) 
CACO-2 cells 
Human colon carcinoma cells 
German Collection of Microorganisms 
and Cell Cultures (Braunschweig, 
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Germany) 
U 937 cells 
Human promonocytic cell line 
 
 
 
2.1.10 Buffers 
 
Deionizised Formamide    500 ml Formamide   
+50 g Mixed-bed resin (Bio-Rad 501-X8) 
      Incubation at 4°C for 30 min, afterwards filtered,   
stored at -20°C 
 
Denhardt Solution       1% (w/v) BSA 
     1%  (w/v)  Ficoll  400 
     1%  (w/v)  Polvinylpyrrolidon 
     sterile  filtered, stored at -20°C 
 
FAB      80%  (v/v)  Formamide 
     1   m M   E D T A  
     4 0   m M   P I P E S  
     400  mM  NaCI 
 
Fixingsolution (10 ml)     9,6 ml PBS 
284 µl Formaldehyd 37% (1% endkonzentration) 
100 µl  Glutaraldehyd 25% (0,25% 
endkonzentration) 
  
FLB  80     80%  (v/v)  Formamide 
     1   m M   E D T A  
     1   x   T B E  
     0,05%  (w/v)  Bromphenol  blue 
     0,05%  (w/v)  Xylenecyanol 
 
Hybridisation Buffer     250ml deionizesed formamide 
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(Northern Blot)      125 ml SSC  
     50  ml  50x  Denhardt  Solution 
     50  ml  10%  SDS 
     2 0   m l   H 2O 
     50  g  Dextransulfat 
     stored  at  -20°C 
 
Hybridisation Buffer  (3x)    12% (w/v) Ficoll 
(EMSA)                60 mM Hepes ph7,9 
     150  mM  KCl 
     3   m M   E D T A  
     3   m M   D T T  
     3   m M   P M S F  
     0,75  mg/ml  BSA 
     stored  at  -20°C 
 
Laemmli-buffer (4 x)    125 mM Tris/HCI pH 6,8 
     1 0 %   ( w / v )   S D S  
     50  mM  Dithiothreitol 
     3 0 %   ( v / v )   G l y c e r o l  
     0,01%  (w/v)  Bromphenol  blue 
 
LB      l%  (w/v)  Trypton 
     0,5%  (w/v)  Yeast  extract 
     1 %   ( w / v )   N a C l  
 
 
LB-agar     1  %  (w/v)  Trypton 
     0,5%  (w/v)  Yeast  extract 
1% (w/v) NaCl 
     1,5%  (w/v)  Agar 
 
Lysis-buffer         300  mM  NaCl 
 50 mM TrisHCl pH 7,6 
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 0.5% Triton X-100 
 supplemented with protease inhibitor cocktail  
 
10xMOPS  (ph7,2):      0,4M      MOPS 
     0 , 1   M     N a - a c e t a t  
     0 , 0 1   M   E D T A  
 
10xPAGE     250  mM  Tris 
     1   %   ( w / v )   S D S    
     520  mM  Glycin   
  
10 x PBS (pH 7,4)      1,3 M NaCl 
     3 0   m M   N a H 2P04
70 mM Na2HP04  
 
RNase buffer       10 mM TRIS/HCl pH 7,5 
     0,3  M  NaOAc  pH7,0 
     5   m M   E D T A  
 
 
SOB –Medium      2% (w/v) Bacto Trypton 
     0,5%  (w/v)  Yeast  Extract 
     1 0   m M   N a C l  
     2 , 5   m M   K C l  
     1 0   m M   M g C l 2  
     1 0   m M   M g S O 4
 
SOC –Medium      2% (w/v) Bacto Trypton 
     0,5%  (w/v)  Yeast  Extract 
     1 0   m M   N a C l  
     2 , 5   m M   K C l  
     1 0   m M   M g C l 2  
     1 0   m M   M g S O 4
     20  mM  Glucose 
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STET      8%  (w/v)  Saccharose   
50 mM Tris/HCI pH 8,0 
50 mM EDTA pH 8,0 
0,1% (v/v) Triton X-100   
 
20 x SSC (pH 7.0)      3 M NaCl   
     0,3  M  Sodium  citrate  pH  7,0 
      
 
50 x TAE        2 M Tris   
     1  M  Acetic  acid 
     5 0   m M   E D T A   
 
 
TB – Buffer(ph 6,7)     10 mM Pipes 
     1 5   m M   C a C l 2 
     250  mM  KCl 
     5 5   m M   M n C l 2  
 
 
100 x Mg
2+-buffer                         100 mM MgCl2 
                                            5 mM 2- mercaptoethanol 
 
 
 
0.1 M NaP04-buffer                     100 ml of 0.1 M Na2HPO4
                                          adjusted to pH 7,3 at 37°C using    
                                          0.1 M NaH2P04  
 
ONPG-solution                            4 mg/ml in OJM NaP04 buffer 
 
 
Stainingsolution (10ml)            8,75 ml PBS 
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1 ml Ferro-Ferri (Endkonzentration 10%) 
250 µl X-Gal-Lösung (Endkonzentration 2,5%) 
25 µl MgCl2  (1M, Endkonzentration 0,25%) 
 
Stop solution                                1 M Na2CO3 solution 
 
10  xTBE     0,45  M  Tris   
     0,45  M  Boric  acid 
     1 0   M   E D T A  
 
50 x TBST        0,1 M  Tris 
     1 , 5   M   N a C l  
     5%  (V/V)  Tween  20 
 
Transfer buffer       25 mM Tris 
(Western blot)      192 mM Glycine pH 8,3 
     20%  (v/v)  Methanol 
 
Puffer A (cytosolic extract):  10 mM Hepes (pH 7,5) 
     1 0   m M   K C l  
     0 , 1   m M   E D T A  
     0 , 1   m M   E G T A  
       Complete  protease  inhibitor  (freshly  added) 
 
Puffer B (nuclear extract):   20 mM Hepes (pH 7,5) 
     0 , 4 M   N a C l  
     1   m M   E D T A  
     1   m M   E G T A  
     1   m M   D T T  
     Complete  protease  inhibitor  (freshly  added) 
 
All buffers were prepared with highly purified water from a Milli-Q-system (Millipore). 
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2.1.11  Buffers, media and sera for cell culture 
 
Dulbecco's modified Eagles medium   Gibco,  Berlin 
Phosphate  buffered  saline     Gibco,  Berlin 
Fetal  calf  serum      Gibco,  Berlin 
Penicillin/Streptomycin     Gibco,  Berlin 
Trypsin/EDTA      Gibco,  Berlin 
 
 
2.1.12 Computer Software 
 
DNA/protein homology search  BLAST search (National Center of 
Biotechnology, USA; URL: 
http://www.ncbi.nlm.nih.gov) 
 
Graphic processing  Corel Draw 8.0/10 
Presentations Powerpoint  2000 
Statistical analysis  Sigma Plot 4.0/5.0 
Text processing  Microsoft Word 2000 
Vector design  Clone Manager 5.02 
 
Programs belonging to special devices are mentioned separately in the appropriate 
sections. 
 
2.1.13  Statistics 
For experiments using DLD-1and U937 cells data are shown as means ± SD. For 
experiments with PBMC data are shown as means ± SEM. Data are presented 
either as pg/ml, as ng/ml, or as fold-induction compared to unstimulated control and 
were analyzed by unpaired Student´s t test (DLD-1,U937 cell experiments) or 
paired Student’s t test (PBMC experiments) on raw data using Sigma Plot (Jandel 
Scientific). 
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2.2 Methods 
2.2.1 Cell culture  
 
All cell lines were cultured at 37°C in a humidified atmosphere containing 5% CO2 
(Heraeus BBD 6220 incubator). For subcultivation, cells were washed once in 
phosphate-buffered saline (PBS), subsequently trypsinized (Trypsin, EDTA) and 
diluted in a 1:5-20 ratio. For long-term storage, the cells were treated as follows: 
after trypsinization, cells were concentrated (5 min at 1100 rpm, Heraeus Megafuge 
1.0, rotor 75750F), washed with PBS, concentrated as above, diluted in freezing 
medium (growth medium supplemented with 10% DMSO) and stored in cryotubes 
(Nunc). The cryotubes were cooled down slowly (1°C per minute to -80°C) and 
finally stored in liquid nitrogen . 
 
2.2.1.1 Cultivation of DLD-1 and Caco-2 colon carcinoma cells  
 
Human DLD-1, Caco-2 colon carcinoma/epithelial and U937 cells were obtained 
from the Centre for Applied Microbiology & Research (Salisbury, United Kingdom) 
and the German Collection of Microorganisms and Cell Cultures (Braunschweig, 
Germany). The colon carcinoma cells were maintained in DMEM supplemented 
with 100 U/ml penicillin, 100 µg/ml streptomycin, and 10% heat-inactivated FCS 
(GIBCO BRL, Eggenstein, Germany). For the experiments, confluent cells on 
polystyrene plates (Greiner, Frickenhausen, Germany) were washed with PBS and 
incubated in the aforementioned medium. Cells were then incubated for varying 
periods on fresh DMEM containing the factors or reagents of interest. 
 
 
2.2.1.2 Cultivation of U937 cells 
 
The human macrophage cell line U937 was maintained in RPMI1640 buffered with 
25 mM hepes (Gibco Life Technologies) containing 10% FCS (Gibco Life 
Technologies), 2 mM L-glutamate, 100 U/ml penicillin, 100 µg/ml streptomycin 
(Gibco Life Technologies). Before each stimulation the medium was changed. To 
pellet the cells (U937 cells are nonadherend cells) they were centrifuged for 5 min 
  34Materials and Methods 
 
at  1000 rpm (Heraeus Megafuge 1.0, rotor 75750F). Cells were then incubated for 
varying periods on fresh RPMI containing the factors or reagents of interest. 
 
 
2.2.1.3 Isolation, cultivation and stimulation of peripheral blood mononuclear 
cells (PBMC) 
 
The study protocol and consent documents were approved by the Ethik 
Kommission of the Klinikum der Johann Wolfgang Goethe-Universität, Frankfurt am 
Main. Healthy volunteers abstained from any drugs during 2 weeks before the 
study. Blood was drawn into heparinized syringes (10 U/ml final concentration) and 
PBMC were isolated by centrifugation through Ficoll (Histopaque-1077, Sigma 
Biochemicals) for 15 min at 2000 rpm (Heraeus Megafuge 1.0, rotor 75750F). Cells 
obtained by this procedure were then washed three times with PBS. PBMC were 
resuspended in RPMI 1640 supplemented with 25 mM HEPES, 100 U/ml penicillin, 
100 µg/ml streptomycin (Gibco Life Technologies) and 1% (v/v) heat-inactivated 
human serum (Sigma Biochemicals) and seeded at 3 x 10
6 cells/ml in round-bottom 
polypropylene tubes.  
 
2.2.1.4 Measurement of cell parameters 
 
 2.2.1.4.1 Cell viability 
 
At the experimental time points of interest, cells were trypsinized (1x Trypsin/EDTA) 
and diluted in fresh DMEM. One part of the cell suspension was mixed with one 
part of 0.4% trypan blue (Gibco Life Technologies) and incubated for 3 min at room 
temperature. Subsequently, unstained (viable) and stained (non-viable) cells were 
counted using a Neubauer chamber. 
 
 
 
 
  35Materials and Methods 
 
 
 2.2.1.4.2 Apoptosis 
2.2.1.4.2.1 Detection of cell death by analysis of cytosolic oligosome-bound                          
                  DNA and release of lactate dehydrogenase (LDH) activity 
 
Apoptotic cell death is characterized by membrane blebbing, condensation of 
cytoplasm and the activation of endonucleases which cleave double stranded DNA 
at the most accessible internucleosomal linker regions, finally generating mono- 
and oligonucleosomes. As DNA degradation occurs several hours before plasma 
membrane disassembly, these mono- and oligonucleosomes are enriched in the 
cytoplasm of apoptotic cells. The ELISA determins soluble DNA/histone complexes 
as a readout for cellular rates of apoptotis (Cell Death Detection ELISA, Roche 
Biochemicals). Cytosolic oligonucleosome-bound DNA is quantified. Absorbance 
values (OD 405/495 nm) give a relative measure of ongoing DNA fragmentation, a 
common marker for cell death by apoptosis. 
Release of LDH which is normally only intracellular in a high concenration is also 
an indicator for ongoing apoptosis that was determined using an assay-kit 
according to the manufacturer´s instructions (Boehringer Mannheim). 
 
 
2.2.1.4.3 Nitric oxide synthase activity, as determined by the amounts of 
nitrite produced using the Griess reagent 
 
Nitrite, a stable NO oxidation product, is determined with the Griess reaction (Green 
et al. 1982) and used as a direct readout for nitric oxide synthase activity. Cell 
culture supernatants were cleared by centrifugation (5 min at 400 g). 100 µl of the 
cleared lysates or supernatants were mixed with 100 µl Griess reagent (Merck). 
After 5 min at room temperature, the absorbance was measured at 540 nm with a 
reference wavelength at 595 nm. 
2.2.2  Bacterial culture 
 
The E. coli strains DH5α (Gibco Life Technologies) and XL1-blue (Stratagene) were 
used for amplification of plasmid DNA. Both strains were either grown in liquid LB 
(Lauria-Bertani) or SOC medium. For selection, the media contained ampicillin (50 
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µg/ml). Agar-plates were generated with LB-ampicillin medium supplemented with 
agar (15 g/l). For long-term preservation of transformed bacteria (2.5.2), cells were 
mixed with sterile glycerol [30% (v/v)] and stored at –80°C. 
 
2.2.2.1 Competent bacteria for transformation 
 
To yield high transformation efficiencies from plasmid DNA in bacteria, cells have to 
be pretreated chemically. To this end, 250 ml SOB-Medium were inoculated with 
200 µl of an overnight bacterial culture and grown at 18°C until the suspension 
reaches an optical density of 0.5 (OD600 nm). The bacterial growth was stopped by 
storing the suspension for 10 min on ice. Bacterial cells were concentrated by 
centrifugation (15 min, 2500g, 4°C; Heraeus Megafuge 1.0, rotor 7570F). The 
cellular pellet was subsequently resuspended in 80 ml solution TB, mixed and 
incubated on ice for 10min. The bacterial suspension was centrifuged again (15 
min, 2500 g, 4°C), the pellet was gently resuspended in 20 ml of solution 
TB+7%DMSO and incubated on ice for additional 10 min. Aliquots of competent 
bacteria were snap frozen in liquid nitrogen and stored at –80°C. 
 
 
2.2.2.1.1 Transformation 
 
100 µl of a competent bacteria suspension (2.2.2.1) was thawed on ice and 1-5 µl 
of the ligation reaction containing recombinand plasmids (see 2.2.3.7.2) were 
added. The bacteria/DNA mixture remained on ice for additional 30 min followed by 
an incubation at 42°C for 30 s. The bacteria were chilled on ice again for 2 min, 
before 400 µl of SOC-medium was added. For initial expression of plasmids 
encoding ampicillin resistance, bacteria were incubated for 45 min at 37°C on a 
shaker. Subsequently, 100 µl of this transformation culture was plated on ampicillin 
containing agar plates. To enable a blue/white screening for recombinant clones, 
the agar plate was supplemented with 50 µl X-Gal (2% in DMF) and 50 µl IPTG (0.1 
M in Aquadest). The plates were incubated overnight at 37°C. 
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2.2.3 Nucleic acid techniques 
 
2.2.3.1 Preparation of plasmid DNA 
 
Plasmids have been routinely isolated from bacteria cultures using a modified 
protocol originally described by Birnboim and Doly (1979). 3 ml of medium 
containing the appropriate antibiotic(s) were inoculated with a single bacterial 
colony from a selective agar plate and incubated overnight by vigorous shaking at 
37°C. 1.5 ml of the cell-suspension was centrifuged for 2 min at 7000 g, and the 
medium was removed carefully by aspiration. The bacterial pellet was resuspended 
in 100 µl of solution I. Subsequently, 200 µl of freshly prepared solution II were 
added to the dispersed bacteria, mixed five times by inverting the tubes and stored 
on ice for exactly five minutes. This step lyses the bacterial cells and denatures the 
DNA. The lysate was neutralized by 150 µl acidic potassium buffer (solution III), 
which was gently mixed after addition and stored on ice for additional 10 minutes. 
The high salt concentration causes SDS to precipitate, and the denatured proteins, 
cellular debris and chromosomal DNA become trapped by salt-detergent 
complexes. Plasmid DNA, being smaller and covalently closed, renatures correctly 
and remains in solution. The tube was centrifuged for 10 min at 15,000 g and the 
supernatant containing the plasmids transferred to a fresh Eppendorf tube. A 
subsequent cleaning step using phenol/chloroform was performed optionally, as 
trace amount of phenol could disturb subsequent enzymatic reactions processing 
the plasmid-DNA. Plasmid-DNA was precipitated using 2 volumes of ethanol at 
room temperature and a centrifugation step for 10 min at 15,000 g. The pellet was 
air dried for 10-15 min and the DNA was finally dissolved in 15 µl of TE-RNAse.  
High amounts of pure plasmid DNA (up to 100 µg) were prepared using the 
QIAGEN Plasmid Midi Kit or for transfections the QIAGEN ENDOFREE Plasmid 
Maxi Kit as described by the manufacturer. 
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Solution 
components 
Solution 
I 
Solution 
II 
Solution 
III 
Glucose 50  mM ---  --- 
Tris/HCl (pH 
8.0) 
25 mM   ---  --- 
EDTA (pH 
8.0) 
10 mM  ---  --- 
NaOH ---  200  mM  --- 
SDS ---  1%  --- 
KOAc (pH 5.5, 
adjusted 
with glacial 
acetic acid) 
--- ---  3  M 
 
 
2.2.3.2  RNA isolation  from cultured cells 
 
RNA isolation was performed with TRI-Reagent according to the protocol from the 
manufactor (Sigma Chemicals, Deisenhofen). Cells were grown and stimulated as 
described above (2.2.1). Last traces of media were removed by a pipette tip 
attached to a vacuum line. Subsequently, cells were lysed with 1ml of TRI-Reagent 
per 10 cm-plate, the lysate was transferred into an Eppendorf tube. After addition 
200 µl chloroform, the samples were inverted five times. The inverted tubes were 
incubated at room temperature for 5 min, centrifuged (15,000 g, 15 min) and the 
aqueous upper phase was transferred into a fresh tube. RNA was precipitated 
using 500 µl of Isopropanol, and isolated by a single centrifugation step (15,000 g, 
15 min). The RNA pellet was washed in cold DEPC-treated water/70% Ethanol, 
followed by a centrifugation (15,000 g, 10 min). The final RNA pellet was 
resuspended in 50 µl DEPC-treated water. Following a 10 min incubation at 55°C, 
the amount of isolated RNA was quantified photometrically (2.2.3.3). 3 µg of the 
isolated RNA was controlled for integrity by agarose gel electrophoresis (1%, 1x 
TBE buffer). Finally, RNA was stored at  –20°C until use. 
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2.2.3.3 Quantification of nucleic acid concentrations 
 
Concentrations of nucleic acids were determined photometrically using a 
wavelength of  260 nm (Gene Quant II, Amersham Pharmacia). An optical density 
(OD) of 1 corresponds to approximately 50 µg/ml double-stranded DNA or 40 µg/ml 
for single stranded DNA and RNA (Sambrook et al. 1989). The ratio between the 
readings at 260 nm and 280 nm (OD260/OD280) provides an estimation of the purity 
of the nucleic acid preparation. Highly pure DNA or RNA are characterized by ratios 
between 1.8 and 2.0.  
The concentrations were calculated according to the following equation: 
C[µg/ml] = OD260 x V x F 
V = dilution factor 
F = multipication factor (dsDNA = 50; RNA = 40) 
 
Low amounts of DNA were estimated by agarose gel electrophoresis (2.2.3.4) in 
comparison with a known standard concentration. 
 
 
2.2.3.4 Agarose gel electrophoresis of nucleic acids 
 
Nucleic acids were usually separated by gel electrophoresis using agarose gels. 
The gel strength was dependent on the molecular weight of the analyzed nucleic 
acids. Agarose (Roth/Gibco Life Siences) was dissolved in 1x TBE gel 
electrophoresis buffer. Ethidium bromide was added to a final concentration of 500 
ng/µl. Ethidium bromide binds to DNA or RNA by intercalation between the bases 
and, thus enables an ultraviolet fluorescence illumination of nucleic acids. The 
DNA/RNA probes were diluted with loading buffer [6x loading buffer: 30% glycerol 
(v/v), 0.25% bromophenol blue (w/v), 0.25% xylenecyanole (w/v), 60% 10x TBE 
buffer (v/v)] and transferred into the appropriate gel wells. Electrophoresis was 
performed in 1x TBE buffer with a voltage of 5-10 V/cm gel. DNA fragment sizes 
were estimated using molecular weight markers (MBI Fermentas).  
For separation of DNA molecules from 0,5 to 7 kbp normally 1%age ([w/v] Agarose) 
gels were used. Smaller DNA fragmentes ( 500bp -100bp) were separated in gels 
with higher densities (mostly 2%) (Sambrook et al., 1989). 
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2.2.3.5  DNA isolation from agarose gels 
 
The use of the Quick Spin Purification Kit (Machery & Nagel) enables a pure 
extraction of DNA fragments directly from agarose gels. The system is based on a 
silica matrix, which binds single and double stranded DNA. The DNA fragments of 
interest were cut from the gel with a razor blade and further processed according to 
the instructions of the manufacturer. 
 
 
2.2.3.6  Reverse transcriptase polymerase chain reaction 
 
2.2.3.6.1  Reverse transcription 
 
The enzyme reverse transcriptase, originally discovered in RNA tumor viruses, 
synthesizes a complementary DNA strand using RNA as a template. This 
enzymatic activity provides access to the generation of cDNA. Random hexamers 
(50 ng/µl) were used as internal enzyme start sites. 
 
 
Reverse transcriptase reaction:  X µl (max. 3 µl)  RNA (1 µg)     
4 µl  MgCl2 (25 mM) 
2 µl  10x PCR-Buffer 
2 µl  dATP (each 10 mM) 
dCTP 
dGTP 
dTTP 
1 µl  RNase Inhibitor (20U/µl) 
1 µl  Random Hexameric Primers (50 µM)
1 µl  Reverse Transcriptase 
(50U/µl; Muloney Virus) 
Applied Biosystems Applera 
X µl  DEPC H2O 
20 µl  Total Volume 
 
1 µg of total RNA was added to the reagents as listed in the table. The reaction was 
performed for 30 min at 42°C. Subsequently the mix was terminated by incubation 
for 5 min at 99°C and cooled to 4°C. Aliquots of the cDNAs were stored at 4°C. 
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2.2.3.6.2 Polymerase chain reaction (PCR) 
 
This methods enables in vitro amplification of DNA fragments without time 
consuming cloning and identification steps (Mullis & Foloona, 1987). The method is 
based on the availability of heat-stable DNA polymerases which allow multiple 
denaturing of template DNA, annealing of driver sequences (primer) and synthesis 
of DNA by amplification steps within one tube. 
 
Polymerase chain reaction:  2 µl
X µl
X µl
RT-product (2.2.3.6.1) or 
Plasmid-DNA Template (5-10 ng) or 
genomic-DNA Template (250 ng) 
5 µl 10x PCR-Buffer 
3 µl MgCl2 (25 mM) 
1 µl dATP (each 10 mM) 
dCTP 
dGTP 
dTTP 
5 µl Forward/Reverse Primer-Mix (5 µM) 
0.4 µl   Taq-Gold Polymerase (5U/µl) 
X µl DEPC H2O 
50 µl Total Volume 
 
The reaction was performed in a thermocycler (GeneAmp 2400 or 9600, PE 
Biosystems). Conditions varied depending on the gene of interest, the type of 
polymerase used for amplification and the experimental set up. For semi-
quantitative gene analysis taq-gold polymerase was used. This enzyme has to be 
activated by a single incubation for 10 min at 94°C (hot start!). In general, 25-30 
cycles of the following steps have been carried out: 1 min 94°C, 1 min 60°C 
(primer-annealing) and 2 min 72°C (elongation). The amplification was completed 
by a final 7 min incubation step at 72°C. Depending on special conditions of 
template, primers and type of cell the protocol was adapted individually (see table 
below). The samples were stored at 4°C and analyzed by gel electrophoresis. 
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Semi-quantitative gene analysis for  Annealing temperature   Cycle number 
GAPDH 60°C  23-25 
hiNOS 62°C  30-32 
IL8 60°C  28 
IP10 60°C  30 
 
 
For amplification of genomic DNA taq and (turbo)-pfu-polymerase has been 
used. In contrast to taq polymerase the (turbo)-pfu polymerase provides 
proofreading activity, at a reduced rate of synthesis. 30–35 cycles were sufficient to 
amplificate genomic IL-8 promotor fragments by using to following PCR program: 1 
min 94°C, 1 min 60°C  and 2 min 72°C. Finally, the amplification was completed by 
a 7 min incubation step at 72°C. 
 
 
2.2.3.7 Cloning of PCR products 
 
After amplification, RT-PCR products were cloned into the pBluescript II (+) KS 
vector (Stratagene) or the TOPOII vector (Invitrogen). To this end, the DNA 
fragments were separated in a agarose gel, cut out and isolated with the Quick Spin 
Purification KIT (2.2.3.5). The DNA fragment of interest was reamplified by pfu-
polymerase (Stratagene) (not in case of cloning into the TOPOII vector), purified by 
gel electrophoresis and ligated into the pBluescript II (+) KS vector at the EcoRV 
restriction site as described in 2.2.3.7.2 or ligated into the TOPOII vector at the 
multiple cloning site according to the instruction manual of Invitrogen. 
 
 
2.2.3.7 Manipulation of DNA 
 
2.2.3.7.1  Restriction 
 
Type II endonucleases isolated from bacteria specifically bind palindromic 
sequences with a subsequent cleavage of the DNA molecule at their recognition 
site. This process generates either blunt-end fragments or overhanging cohesive 
ends, which allow the generation of recombinant DNA by enzymatic ligation. The 
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standard approach for DNA digestion is subsequently listed. After incubation at the 
appropriate temperature, DNA cleavage was checked by agarose gel 
electrophoresis (2.2.3.4). 
 
DNA digestion:  17.8 µl   DNA (500 ng) 
2.0 µl    1 f r
0.2 µl    r o
units) 
0x buf e  
estricti n enzyme (3 
 
 
 
2.2.3.7.2 Ligation 
 
Generation of covalent phosphodiester bonds between the 5´-phosphate and the 
3´-OH of DNA fragments is catalyzed by T4-DNA ligase. The ligation reaction was 
performed with restricted or PCR amplified DNA. The desired DNA fragments were 
directly purified with a Quick Spin Colum (Machery& Nagel) or after separation by 
agarose gel electrophoresis. The mixture was incubated for up to 16h at room 
temperature. Thereafter, an aliquot of this reaction was transformed into competent 
bacteria as described in section 2.2.2.1.1. 
 
DNA ligation:  4 µl   10x ligase buffer 
1 µl   vector DNA (500 ng) 
10 µl   DNA fragment 
1 µl   T4-DNA ligase (1 unit) 
ad 40 µl   H2O 
 
 
2.2.3.7.3  Dephosphorylation 
 
If the vector DNA carried complementary cohesive termini after enzymatic 
restriction, the plasmid was treated with alkaline phosphatase (Roche 
Biochemicals) prior to ligation. Phosphatases remove the 5´-phosphates from DNA 
strands. This technique prevents a religation of restricted plasmids without 
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incorporation of insert DNA. To this end, the restricted DNA was incubated with 
alkaline phosphatase (0,1 unit/µg DNA) for 30 min at 37°C. Afterwards, the 
phosphatase was heat-inactivated for 10 min at 70°C and the denatured protein 
extracted with phenol/chloroform. The ligation of the DNA fragments was performed 
as described in 2.6.6.2. 
 
 
2.2.3.7.4  DNA sequencing 
 
DNA sequencing was performed using the ABI-Prism 310 Genetic Analyser (PE 
Biosystems) based on the dideoxynucleotide chain termination method (Sanger et 
al. 1977). In the termination labeling mix, the four dideoxy terminators (ddNTPs) are 
tagged with different fluorescent dyes. This technique allows the simultaneous 
sequencing of all four reactions (A, C, G, T) in one reaction tube. The probes were 
separated electrophoretically using a micro capillary. As each dye terminator emits 
light at a different wavelength when excited by laser light, all four colors 
corresponding to the four nucleotides can be detected and distinguished within a 
single run. Raw data were evaluated by the Abi Prism sequencing analysis software 
on a Power G3 Macintosh computer. The sequencing reaction, as listed in the 
table, was performed in a thermocycler (GeneAmp 2400, PE Biosystems) with 25 
cycles of the following temperature steps: 96°C for 10 sec, 55°C for 5 sec, 60°C for 
2 min. For the detection process, samples were prepared as described by the 
manufacturer. 
 
DNA sequencing:  1 µl  DNA (250 ng plasmid DNA 
or 50 ng PCR derived 
DNA) 
2 µl  sequencing premix 
1 µl  primer (5 pmol) 
6 µl  H2O 
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2.2.3.8  RNase protection assay 
 
This method was used to quantify the amounts of specific RNA transcripts from 
total cellular RNA. Compared to Northern blot analysis, this technique possesses 
increased sensitivity and specificity. The assay is based on the principle, that 
double stranded RNA hybrids were protected from cleavage by RNases A and T1. 
 
2.2.3.8.1 DEPC-treatment 
 
Buffers and solutions for RNA based methods were treated with diethyl 
pyrocarbonate (DEPC) to inactivate RNases. Note that DEPC reacts with amines 
such as Tris. Hence, buffers containing amines were made from DEPC treated 
water, but not treated with DEPC directly. DEPC treated water was obtained by 
adding 1 ml DEPC per liter of Aq. dest. After mixing in an overnight step at RT, the 
solution was autoclaved. 
 
2.2.3.8.2 Preparation of a radiolabeled antisense probe  
 
The desired probes (150-450 nt in length) were cloned into the transcription vector 
pBluescript II KS (+) as described in section 2.2.3.6.3. The recombinant plasmids  
were linearized with restriction enzymes, phenol/chloroform extracted, precipitated 
and dissolved in Aquadest to a final concentration of 1 µg/µl. A pure single stranded, 
[α-
32P]UTP radiolabeled antisense transcript was synthesized using T3 or T7 RNA 
polymerase. The reaction mix was prepared as listed in the table and incubated for 
1 h at 37°C. 
 
In vitro 
transcription: 
1.1 µl  H2O, DEPC-treated 
  1.0  µl  nucleotides (ATP, CTP, GTP; each 5 
mM)  
  2.0 µl  transcription buffer (5x) 
  0.4 µl  RNasin (40 U/µl) 
  1.0  µl  T3 or T7 RNA polymerase, depending 
on the vector 
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 2.5  µl  [α-
32P]UTP (800 Ci/mM) 
  1.0 µl  Linearized template (1 µg/µl) 
 
Subsequently 90 µl DEPC-H2O were added. The reaction was extracted with an 
equal volume of phenol/chloroform and centrifuged (15,000 g, 2 min). The 
radiolabeled RNA was precipitated form the aqueous phase using 40 µl of 7,5 M 
ammoniumacetate, 1,5 µl of tRNA (10 µg/µl) and 350 µl of ethanol for 15 min at –
20°C. Following a 15 min centrifugation step at 4°C, the radiolabeled pellet was 
dissolved in 20 µl FLB 80 and purified using an acrylamide/urea gel (5% 
acrylamide/bisacrylamide, 29:1; 8 M urea; 1x TBE). Electrophoresis (1x TBE buffer, 
300 V) was terminated after 90 min. The radiolabeled probe was located by 
autoradiography, cut out and eluated into 300 µl elution buffer (0,1x TBE, 0,2% 
SDS). The incorporated activity of the freshly prepared radiolabeled probe was 
determined using a β-counting device (TRI-CARB 2100 TR, Canberra-Packard). 
 
 
2.2.3.8.3 Hybridization and cleavage 
 
10-30 µg of total RNA from cell culture experiments (see 2.2.3.2) were used for the 
experiments. Total RNA and 100,000 cpm of the radiolabeled probe were co-
precipitated using a 2,5-fold excess of ethanol/0,1 M NaOAc. The samples were 
incubated at –20°C for 15 min and subsequently centrifuged (15,000 g, 10 min). 
The supernatants were removed and the RNA/antisense probe pellet was 
resuspended carefully in 30 µl FAB hybridization buffer. Samples were 
subsequently denatured for 10 min at 85°C and hybridized overnight (42°C in a 
water bath). Thereafter, samples were treated with 300 µl RNase T1/A-mix (RNase 
buffer supplemented with 10 µg of RNase A and 200 units of RNase T1) for 1 h at 
30°C (Melton et al. 1984)]. Under these conditions, every single mismatch was 
recognized by the RNases. RNases were inactivated by an addition of 6,6 µl SDS 
(10%) and 4,4 µl proteinase K (10 µg/ml) for 15 min at 42°C. The samples were 
extracted with phenol/chloroform and centrifuged (15,000 g, 2 min). Protected 
double-stranded RNA hybrids were precipitated using 880 µl of ethanol and 1,5 µl 
of tRNA (10 µg/µl). After centrifugation, (15,000 g, 15 min), the pellet was 
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resuspended in 25 µl FLB 80 buffer, heated for 5 min at 95°C and loaded on the 
gel. 
 
 
2.2.3.8.4 Analytical gel electrophoresis and signal detection 
 
The protected RNA fragments were separated on acrylamide/urea gels (5% 
acrylamide/bisacrylamide, 29:1; 8 M urea; 1x TBE). 1000 cpm of the radiolabeled 
antisense probe served as a size marker. Electrophoresis (300 V, 1x TBE buffer) 
was stopped after 60 min. The gel was fixed on Whatman 3MM paper and 
subsequently dried on a gel drying system (Bio Rad). The radiolabeled gel was 
exposed to a phosphoimager plate (BAS-MP 2040S, Fuji) and analyzed using a Fuji 
PhosphoImager BAS-1500.  
 
 
2.2.3.9  Northern blot analysis 
 
This method is used to quantify the amounts of specific RNA transcripts from total 
cellular RNA. Compared to RNAse Protection Assays, this technique has the 
advantage to be less a source of error. By stripping the membranes (2.2.3.9.3) 
multiple genes can be investigated using the same blot. The assay is based on the 
principle, that immobilized RNA strands on a membrane could specificly hybridize 
to radioactive labeled DNA single strands. 
 
 
2.2.3.9.1 Generation of Probes 
 
The cDNA inserts of human IP-10 and MIG were generated by reverse transcription 
(RT) from mRNA of DLD-1 cells stimulated with IL-1β and IFNγ. The following 
primers were used for MIG: 5’-GCT GGT TCT GAT TGG AGT GC-3’ (for) and 5’- 
TGA CGA GAA CGT TGA GAT TTT C-3’ (rev) for IP-10: 5’-AGT GGC ATT CAA 
GGA GTA CC-3’ (for) and 5’-ATC CTT GGA AGC ACT GCA TC-3’ (rev). The sticky 
ended fragments were cloned into the multiple cloning site of the Top-II-Vector 
(Clontech, Germany). The cDNA fragments were exised by a EcoRI digestion. 
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2.2.3.9.2  Preparation of a radiolabeled antisense probe  
 
The desired probes (300-1000nt in length) were cloned into the transcription vector 
TOPO II  (+) as described in section 2.2.3.6.3. The fragments of interest were   
cleaved out of the recombinant plasmids by use of the restriction enzyme Eco RI 
(MBI Fermentas, Litauen), gel isolated, extracted with Quick Spin Tubes and 
brought  to a final concentration of 10 ng/µl. A pure single stranded, [γ-
32P]dCTP 
radiolabeled antisense transcript was synthesized using the Rediprime Labelling 
Mix (Amersham RPN1633) according to the manufactor’s protocol. The labeled 
probe was cleaned up by using Nick Colums (Amersham, Pharmacia) according to 
the manufactor’s protocol. 
 
 
2.2.3.9.3 Analytical gel electrophoresis and signal detection 
 
Total cellular RNA was extracted from DLD-1 cells using the TRI-Reagent as 
described above. Samples of 10 µg of RNA were separated on 1.4% 
agarose/formaldehyde gels and transferred by sandwich blot to a gene screen 
membrane. Membranes used for RNA transfer were obtained from NEN Life 
Science Products (Boston, MA, USA).  
After UV crosslinking with 150 mJ the membrane was stained with Methylenblue to 
check if the transfer of RNA was successfull and the loading of the gel was equal. 
The membrane was destained by incubation first with 20% ethanol then with 0,2 x 
SSC/1%SDS.   After prehybridization for 2h the filters were hybridized for 16h at 
42°C to a 
32P-Iabeled cDNA insert of interest.  DNA probes were radioactively 
labeled with 
32P-dCTP by random priming (Amersham Pharmacia Biotech, 
Freiburg, Germany ). Finally, the filters were washed twice with 2 x SSC/ 0,1% SDS 
for 2 x 20 min at 42°C and several times at 65°C with 0.2 x SSC/1% SDS. To 
correct for variations in RNA amounts the blot was stripped. Thereafter blots were 
finally rehybridized with a 
32P-labeled insert from a human ß-actin cDNA clone. 
Specific signals were detected using, an automated detector system BAS 1500 
from Fujifilm (Raytest, Straubenhardt, Germany). 
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2.2.3.10 Protein techniques  
 
2.2.3.10.1 Preparation of lysates 
 
2.2.3.10.1.1  Cell lysates 
 
Cells were grown and stimulated as described above (2.2.1). For harvesting, cells 
were washed twice with ice-cold PBS. Last traces of PBS were removed by a 
pipette tip attached to a vacuum line. DLD-1 cells were treated with lysis-buffer (300 
mM NaCl, 50 mM TrisHCl, pH 7.6, 0.5% Triton X-100) supplemented with protease 
inhibitor cocktail (Roche, Mannheim, Germany). To remove cellular debris, samples 
were centrifuged (15,000 g, 10 min, 4°C) and the supernatants were stored at –
80°C until use. 
Protein concentrations were determined using the Roth Nanoquant Protein Assay 
(2.2.3.10.1.2). 
 
2.2.3.10.1.2 Determination of protein concentration 
 
The amount of protein in cellular lysates was determined using the Roth Nanoquant 
Protein Assay (Bradford method). 50 µl of the samples (1:5-1:50 prediluted in 
homogenization buffer) were pipetted in duplicate into appropriate wells of a 96-well 
ELISA plate. Different BSA concentrations (20-100 µg/ml) were used as a standard.    
200 µl of Roth solution (1:5 diluted in Aquadest) were added to each well. After 10 
min of incubation, the optical density was measured at a wavelength of 595 nm  
and reference wavelength 450 nm using a microplate reader (Bio Rad). The 
absorption values were calculated using the Microplate Manager 4.0 software (Bio 
Rad). 
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2.2.3.10.2  Western blot analysis 
 
The Western blot technique represents a sensitive method to detect specific 
polypeptides within a complex mixture of proteins. Proteins are separated 
electrophoretically and transferred to a membrane, which is subsequently incubated 
with antibodies specific for the protein of interest. Finally, the bound antibody is 
recognized by a second anti-immunoglobulin that is coupled to horseradish 
peroxidase or alkaline phosphatase.  
 
Buffer 
components 
Laemmli 
buffer 
(4x) 
Electrophoresis 
buffer (1x) 
Transfer 
buffer 
(1x) 
TBST 
buffer 
(10x) 
Tris/HCl  125 mM (pH 
6.8) 
25 mM  25 mM  100 mM (pH 
8.0) 
SDS  10% (w/v)  0.1% (w/v)  ---  --- 
Glycine  ---  250 mM  192 mM  --- 
Dithiothreitol 50  mM  ---  ---  --- 
Bromophenol 
blue 
0.01% (w/v)  ---  ---  --- 
Glycerol 30%  (v/v)  ---  ---  --- 
Methanol ---  --- 20%  (v/v)  --- 
Tween 20  ---  ---  ---  5% (v/v) 
NaCl ---  ---  ---  1.5  M 
 
 
 
2.2.3.10.2.1 SDS gel electrophoresis 
 
Electrophoretic separation of proteins was carried out in the discontinuous buffer 
system for SDS polyacrylamide gels as originally described by Laemmli (1970). 50 
µg of total protein were dissolved in 6x Rothi Load (Roth). After heating for 5 min at 
95°C, samples were loaded on the gel. Subsequently, the gel was run at a current 
of 30 mA for a period of 1-3 hours. 
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Resolving gel 
Component volumes (ml) per 
20 ml gel 
Solution 
components 
6% 
(> 120 
kDa) 
10% 
(60-120 
kDa) 
12% 
(< 60 
kDa) 
H2O 10.6  7.9  6.6 
Acrylamide mix 
(30%) 
4.0 6.7 8.0 
Tris/HCl (1.5 M, pH 
8.8) 
5.0 5.0 5.0 
SDS  (10%)  0.2 0.2 0.2 
Ammonium 
persulfate (10%) 
0.2 0.2 0.2 
TEMED  0.016 0.008 0.008 
 
 
Stacking gel 
Component volumes (ml) per 
gel volume of 
Solution 
components 
2 ml  5 ml  10 ml 
H2O  1.4 3.4 6.8 
Acrylamide mix 
(30%) 
0.33 0.83  1.7 
Tris/HCl (1.5 M, pH 
6.8) 
0.25 0.63 1.25 
SDS (10%)  0.02  0.05  0.1 
Ammonium 
persulfate (10%) 
0.02 0.05  0.1 
TEMED 0.002  0.005  0.01 
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2.2.3.10.2.2  Transfer to PVDF membrane 
 
After gel electrophoresis, proteins were transferred to a polyvinylidene fluoride 
(PVDF) membrane by electroblotting (Trans-Blot SD, Bio Rad). Prior to use, the 
PVDF membrane was activated in isopropanol for 3 min and subsequently rinsed in 
deionized water. Six pieces of Whatman 3MM paper were soaked in transfer buffer 
and positioned on the anode side of the transfer apparatus. The PVDF membrane 
was placed directly on the stack of 3MM paper. The SDS gel containing the 
separated proteins was taken off the glasplates, rinsed shortly in transfer buffer, 
and placed on the top of the PVDF membrane. Finally, the gel was covered with 
four additional, transfer buffer-soaked Whatman 3MM papers. Air bubbles were 
squeezed out by a roller apparatus. The upper electrode (cathode) was positioned 
on the top of the stack and a current of 0,8 mA/cm
2 was applied. Transfer of 
proteins was carried out at room temperature and terminated after 75 min. After 
blotting, the membrane was checked by Ponceau S staining for correct 
electrophoretic transfer and equal loading. 
 
2.2.3.10.3  Staining with Ponceau S 
 
After the protein transfer from gel to membrane always a staining with Ponceau S 
was done. Purpose of this staining was to determine whether the protein transfer 
was sufficient and to check for equal loading. Directly after staining the membrane 
was  scanned in its wet condition and thereafter destained by shaking in destilled 
water.  
 
 
 
2.2.3.10.4  Staining with Coomassie-Brilliant-Blue 
 
After protein transfer the gel was stained in Coomassie-Brilliant-Blue (2,5mg/ml 
Coomassie-Brilliant-Blue G250, 45% Methanol, 45% H2O und 10% acetic acid). 
The gel was decoloured after one hour incubation (20% Methanol, 70% H2O, 10% 
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acetic acid) for more than 12 hours. This procedure was also done to see if the 
proteintransfer was sufficient. 
 
 
2.2.3.10.5  Immunodetection 
 
The air-dried PVDF membrane was reactivated in isopropanol and rinsed in 1x 
TBST buffer. Non-specific binding sites were blocked by shaking the membrane in 
a TBST-buffered non-fat skim milk solution (10%) for 1 h at room temperature or 
overnight at 4°C. The membrane was subsequently exposed to antibodies (diluted 
1:500  1:2000 in 1x TBST buffer) specific for the protein of interest. The incubation 
time varied between 1 h at room temperature, or 15 h at 4°C depending on the 
antiserum. The blot was washed three times for 15 min in 1x TBST. The primary 
antibody was detected by incubation of the membrane with a specific secondary 
antibody coupled to horseradish peroxidase (diluted 1:5000  1:20,000 in 1x TBST) 
for  45 min at room temperature. For detection of the corresponding bands, we 
used the enhanced chemiluminescence (ECL) detection kit (Amersham Pharmacia) 
according to the instructions of the manufacturer. The membrane was exposed to a 
film (Hyperfilm, Amersham Pharmacia) and developed (Hyperprocessor, Amersham 
Pharmacia). Developed films were scanned (GS 700 Imaging Densitometer, Bio 
Rad) and analyzed using the Molecular Analyst software from Bio Rad. 
 
 
2.2.3.10.6  Enzyme-linked immunosorbent assay (ELISA) 
 
The enzyme-linked immunosorbent assay (ELISA) technique is the most sensitive 
method to specifically determine protein concentrations from different sources. 
Sensitivity is approximately 100-fold increased compared to the Western blot 
technique (2.7.4). The ELISA was performed according to the instructions of the 
manufacturer’s (R&D Systems, PharMingen). Briefly, microtiter plates were coated 
with a monoclonal antibody or a specific receptor. Equal volumes of samples were 
pipetted into the wells of the microtiter plate and incubated for 2 h. Subsequently, 
wells were washed. An enzyme-linked antibody specific for the target protein was 
added for 2 hours, and wells were subsequently washed for three times. Wells were 
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then incubated with substrate solution. If the samples have been diluted optimal, 
the color reaction develops in direct proportion to the amount of bound antigen. The 
optical densities were calculated using the Microplate Manager 4.0 software from 
Bio Rad. 
 
Used ELISAs:  • Human IL-8 (PharMingen) 
• Human
• Human
 IP-10 (PharMingen) 
 VEGF (R&D) 
 
 
 
2.2.3.11 Transfection  and  Reporter Gene Assays 
                Plasmid constructs, transient transfection experiments, reporter  
                assays, and mutational analysis 
2.2.3.11.1  Reporter Gene Assays 
Today gene expression and regulation are often examined by transient- und stable 
transfection techniques. One method to examine the regulation of the expression of 
a gene is the reporter gene assay. For this purpose DNA sequenzes in which 
potential regulatory elements are expected are cloned, in front of a reportergene (in 
vectors which contain a minimalpromotor). Reporter genes can be the 
chloramphenicol acetyltransferase (Gorman et al.,1982) or the luciferase ( Alam 
and Cook, 1990). The newly cloned reporter constructs are transferred into 
eukaryontic cells. After transfection the cells are stimulated  with the agent of 
interest. After an appropriate time period that varies depending on the respective 
gene, cells were harvested and the amount of synthesized reporter gene products 
was measured. To clarify the influence of the investigated sequence on the 
genregulation it is necessary to compare the expression of the reporter gene with 
and without the putative regulatory sequence in the plasmid. 
 
2.2.3.11.2  Transfection of eukaryontic cells 
 
Several methods are used to transfere DNA into eukaryontic cells. Mostly applied 
methods are the microinjection, the calcium phosphate transfection, the DEAE-
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Dextran transfection, the electroporation, and the transfection by help of  liposomes 
(artificial membrane vesikel). Substances which could enclose DNA like 
Lipofectamin ( Gibco, Eggenstein) or FuGENE 6 (Roche Boehringer) consist of 
artifical, neutral and kationic lipids. The efficacy with which the liposome-nucleic 
acid-complexes were taken up has a strong variation rate dependending on the cell 
line in use. For this purpose for each cell line a suitible reagent with an individual 
protocol must be established. The molecular mechanisms of transfection are largely 
unknown. Probably the liposomal complex is taken up by endocytosis into the cell 
followed by the transport of DNA from the cytoplasma in to the nucleus. 
 
2.2.3.11.3  Transient transfection  
 
Confluent grown cells were trypsinized and cultured in fresh media. The cells 
should have a confluency of about 50-60%. The cells were seeded in 2ml media 
per well onto six-well-culture-plates and incubated for 18h in an incubator with 
standard conditions. Luciferase expression contructs (750 ng DNA/35 mm-well ultra 
pure) were transfected into DLD-1 cells using FuGENE 6 Transfection Reagent 
(Roche) according to the manufacturer’s instructions we used 3µl of Fugene 
Transfection Reagent per well. Plasmid DNA  and 3µl FuGENE 6 Reagent were 
diluted with  300 µl serum-free medium, combined and mixed gently. The solutions 
were allowed to form DNA-liposome complexes for 30 min at room temperature. 
Target cells were rinsed two times with PBS and added fresh media. The DNA-
liposome complexes were added and incubated with the 2 ml of the diluted DNA-
liposome complex for 36h without replacing the transfection mixture. For control of 
transfection efficiency 500 ng of pCMV-β galactosidase DNA was cotransfected. 
After a 36 h transfection period, cells were washed twice with PBS. DLD-1 cells 
were then either kept as unstimulated control or stimulated with PDTC or TNFα. 
After 8h, cells were harvested and luciferase activity was determined using the 
Promega Luciferase Assay System (Promega, Madison). 
 
 
 
 
  56Materials and Methods 
 
2.2.3.11.4  Construction of the IL-8 promotor and its mutants 
 
The human IL-8 promotor 5’-flanking region from -558 to +98 bp was amplified by 
pfu-polymerase (Stratagene, Gebouw California, Netherlands) from human 
genomic DNA using the oligonucleotides 5’-ctt cac tct gtt aac tag cat ta-3’ (-558/-
535) as forward and 5’-aca cac agt gag aat ggt tcc t-3’ (+76/+98 bp) as reverse 
primer, respectively. The resulting PCR product was cloned into pGL3-promotor 
vector containing a luc+transcriptional unit. Constructs were verified by sequencing. 
Mutations were performed using the QuikChange Site-Directed Mutagenesis Kit 
(Stratagene) according to the manufacturer’s instructions. For the mutations of the 
AP-1, NF-κB, and C/EBPβ sites (Vlahopoulos, S., et al. 1999) the following primer 
sequences were used: activator protein-1 (AP-1) sequence (forward) 5’-aag tgt gat 
atc tca ggt ttg ccc tga-3’, (revers) 5’-caa acc tga gat atc aca ctt cct a-3’; NF-κB 
sequence (forward) 5’-ttg caa atc gtt tta att taa tct gac ata a-3’, (revers) 5’-ttc att atg 
tca gat taa att aaa cga ttt-3’; C/EBPβ sequence (forward) 5’-gcc atc agc tac gag tcg 
tg-3’, (reverse) 5’-gaa att cca cga ctc g ta  gct-3’. Mutations were checked by 
sequencing using the automated sequence analyzer ABI 310 Genetic Analyzer (PE 
Applied Biosystems, Weiterstadt, Germany).  
 
 
2.2.3.11.5  Determination of reporter gene induction 
 
The luciferase of the Firefly ( Photinus pyralis) catalyzes the oxidation of luciferin. 
During this reaction photons at a wavelength of  562 nm were emitted. A 
quantitative measurement of the emitted light is possible by use of a Luminometer.  
Cells were transiently transfected with a luciferase-construct, stimulated, and 
harvested in Reporter-Lysisbuffer according to the manual of Promega. The 
solutions which were needed were prewarmed to room temperature. 20 µl of cell 
extrakt  was pipetted  in a polystyrole tube. These were transfered into the 
Luminometer. The measurement was performed, after injection (in the 
Luminometer) of 100 µl Luciferase Assay Reagent (Promega) (20 mM Tricin, 1,07 
mM (MgCO3)Mg(OH)2 x 5 H2O, 2,67 mM MgSO4, 0,1 mM EDTA, 33,3 mM DTT, 
270 µM Coenzym A, 470 µM Luciferin, 530 µM ATP pH 7,8). The emitted light was 
  57Materials and Methods 
 
measured for 10 sec with a Photomultiplier. Data were expressed as relative Light 
Units (RLU).  
 
 
2.2.3.11.6  Detection of  ß-Galactosidase expression 
 
The ß-galactosidase (β-gal) is a bacterial enzyme which catalyzes the  break down 
of the sugar lactate. This enzyme is encoded by the bacterial Gen lacZ located in 
the lac-Operon of ß-gal. Lactate is not the only substrate wich can be catalysed. An 
alternative substrate that is often used is 5-Bromo-4-chloro-3-indolyl-β-D-
galactoside (X-gal). Its enzymatic degradation by β-gal leads to blue colored 
products. The resulting blue stain of the reaction can be quantified. The lacZ Gen 
under the control of a constitutive promotor was transfected into DLD-1 cells to 
determine the transfection efficacy. Analysis was performed by two different 
staining methods as outlined below.  
 
 
2.2.3.11.7  Histochemical Staining of ß-Gal positive cells 
 
This method was used to establish the transfection method. The advantage of this 
method is that each single cell which is positively transfected could be detected by 
microscopy. The cytosol of positive transfected cells gets blue after histochemical 
treatment. So that the efficacy ot transfection could simply be detected by counting 
the blue cells.    
Protocol of treatment: 
The cells were first washed with PBS and then fixed with glutaraldehyde. For a  
6cm culture dish 3ml fixing and staining solution were used. 
 
The fixing solution (10ml) : 
 9,6 ml PBS 
284 µl Formaldehyde 37% (1% final concentration) 
100 µl  Glutaraldehyde 25% (0,25% final concentration) 
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After 5min incubation the fixing solution was totally removed and cells were washed 
two times with PBS. Afterwards the staining solution was added. Fixing and staining 
solutions have to be prepared freshly before the experiment. 
 
Staining solution (10ml): 
8.75 ml PBS 
1ml Ferro-Ferri (final concentration 10%) 
250µl X-Gal-solution (final concentration 2.5%) 
25µl MgCl2   (1M, final concentration 0.25%) 
 
The cells were transfered into the incubator with the staining solution for several 
hours. After a few hours in positive cells a blue color becomes visible. 
For longer storage the staining solution was removed and replaced by 2% Glycerol. 
The dishes were then enclosed with parafilm and stored in the refrigerator. 
 
 
2.2.3.11.6  Proof of ß-Gal in lysates of transfected cells 
 
This method is used to measure the amount of ß-gal in lysates of transfected cells  
of luciferase assays. The transfection efficacy varies in one experiment upon the 
transfected cells in different wells of the dishes. For control of transfection 
efficiency a constant amount of pCMV-β galactosidase DNA was cotransfected 
with firefly constructs of interest. The pCMV-β galactosidase plasmid contains a 
constitutive promotor which delivers a constant expression of β-gal. The 
determined amount of β-gal was used to set off against the RLUs’ out of the 
luciferase assays (see 2.2.3.11.5).  
 
Buffers and solutions: 
 
100 x Mg
2+-buffer                                100 mM MgCl2
                                                    5 mM 2- mercaptoethanol 
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0.1 M Sodium phosphate-buffer        100 ml of 0.1 M Na2HPO4
                                                adiusted to pH 7.3 at 37
OC using    
                                                0.1 M NaH2P04  
 
ONPG-solution                                  4 mg/ml in O,1 M Sodium phosphate-buffer 
 
Stop-solution                                      1 M Na2CO3 solution 
 
The following reagents were combined: 
10-150 µl of cell extract (extraction for ß-Galactosidase was performed as 
previously described in 2.2.3.11.5 with promega lysis buffer), 3 µl of 
100 x Mg-buffer, 66µl ONPG solution and Sodium phosphate-buffer were added to 
a final volume of 300 µl. The reaction- was incubated at 37°C for 30 min to several 
hours until a yellow color was visible. The reaction was stopped by adding 0.5 ml 
of stop solution. The color reaction was measured photometrically at 410 nm. 
 
 
2.2.3.12  Electrophoretic mobility shift assay (EMSA) 
2.2.3.12  Detection of proteins using EMSA analysis 
 
The EMSA method is to characterize the interaction between a protein and a DNA 
double strand. The gel-shift method relies on the binding of an specific  
32P labeled 
oligonucleotide to a particular DNA binding protein. The nucleotide/protein 
complexes can be separated from the free oligonucleotide on a non denaturating 
acrylamide gel. In contrast to the Western blot method a denaturating gel can not 
be used, because for the interaction of the DNA with the protein, native structure is 
necessary. Proof of the identity of the DNA binding protein can be achieved by 
supershift analysis. In this approach an antibody which is known to bind specifically 
to a protein of interest is added to the reaction mix. If the antibody successfully 
bind to the DNA protein complex the so called supershift may become visible on 
the gel which is due to the higher molecular weight of the antibody/antigen/DNA 
complex. Alternatively, the respective band dissappears if the antibody interferes 
with the DNA binding site of the protein of interest.     
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2.2.3.12.2  Nuclear extrakts 
Subconfluent cells on 10 cm dishes were stimulated for 30 min to 4h washed twice 
with cold PBS and scraped in ice cold 1.5 ml PBS/EDTA (0,1mM (pH8,0)). All steps  
were performed strictly in a cold enviroment (lower than 4°C). The cells were 
pelleted by centrifugation in an cold centrifuge at 13000 rpm for 5 min. The pellet 
was resuspended in 300 µl cold buffer A + 0.6%NP40 + protease inhibitor and 
incubated for 15 min by vigorous shaking at 4°C. Nuclei and cell fragments were 
pelleted by centrifugation in a centrifuge at 13000 rpm and 4°C  for 15 min. The 
supernatant consists of a cytosolic extract which could be used for Western blot 
analysis. The DNA binding proteins in their active form are located in the nucleus. 
Thus the nuclear pellet has to be resuspended in 70µl ice cold buffer C + protease 
inhibitor and incubated for 20 min by vigorous shaking at 4°C. Nuclei and cell 
fragments were pelleted by centrifugation in a centrifuge at 13000 rpm and 4°C for 
5 min. Finally, the supernatant contains the nuclear extracts. Protein concentrations 
were measured as described bevore by the Bradford method. The protein solutions 
were aliquoted, shock frozen in liquid nitrogen and stored at –80°C until use. 
  
 
2.2.3.12.3  Labeling of oligonucleotides 
 
The consensus oligonucleotides which were used in the binding reactions were 
obtained from Santa Cruz Biotechnology (Santa Cruz, CA). Sequences of the 
double-stranded oligonucleotides are as follows, NF-κB: wt 5’-agt tga ggg gac ttt 
ccc agg c-3’; mutated 5’-agt tga ggc gac ttt ccc agg c-3’. AP-1: wt 5’-cgc ttg atg act 
cag ccg gaa-3’. Complementary oligonucleotides were end labeled by T4 
polynucleotide kinase (MBI Fermentas, St. Leon-Roth, Germany) using [γ-
32P]ATP 
(3000 Ci/mmol, Amersham Pharmacia Biotech, Braunschweig, Germany). 
 
Oligolabeling: 2  µl  ds  Oligo (pgml/µl) or 2µl 
consensus 
2 µl  10x Polynucleotide Kinase 
Buffer 
10 µl H2O 
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1 µl  T4 Polynucleotidekinase 
5 µl  [γ-
32P]ATP 
 
 
The reaction mix was incubated for 1h at 37°C. Thereafter the enzyme was heat 
inactivated at 75°C for 10 min and slowly cooled down overnight . The labeled 
probe was cleaned up by using Nick Colums (Amersham, Pharmacia) due to the 
manufactors’ protocoll. The incorporated activity of the freshly prepared 
radiolabeled probe was determined using a β-counting device (TRI-CARB 2100 TR, 
Canberra-Packard). 
 
 
2.2.3.12.4 Binding  reaction, analytical gel electrophoresis and signal  
                     detection 
 
Binding reactions were performed for 35 min on ice with 10 µg of protein in 20 µl of 
binding buffer containing 4% Ficoll, 20 mM HEPES (pH 7.9), 50 mM KCl, 1 mM 
EDTA, 1 mM DTT, 1 mM PMSF, 0.25 mg/ml BSA, 2 µg of poly(dI-dC), and 20,000-
25,000 dpm of 
32P-labeled oligonucleotide. For AP-1 super - shift analysis nuclear 
proteins were preincubated for 15 minutes at room temperature with a polyclonal 
anti-c-jun antibody (Santa Cruz, CA). DNA protein complexes were separated from 
unbound oligonucleotide by electrophoresis through a 4% polyacrylamide gels 
using 0.5 x TBE buffer. 
 
 
EMSA Gel 
Component volumes (ml) per 
36 ml gel  Solution 
components  4,5% 
 
6% 
 
8% 
 
H2O 28,3  27  24,1 
Acrylamide mix 
(30%/0,8%) 
5,4 7,2 9,6 
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10 x TBE  1,8  1,8  1,8 
Ammonium 
persulfate (10%) 
0,4 0,4 0,4 
TEMED  0,3 0,3 0,3 
 
  Thereafter, gels were fixed and analyzed by PhosphoImager analysis (Fuji). 
Competition experiments were performed by coincubation with a 100-fold excess 
(20 pmol) of unlabeled double-stranded oligonucleotide in the DNA-protein binding 
reaction. 
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3 Results 
 
3.1.1 PDTC efficiently augments TNFα-induced IL-8 release and mediates 
production of IL-8 as a single stimulus in DLD-1 cells 
 
While studying the expression of IL-8 in DLD-1 colon carcinoma cells, we 
investigated the effects of PDTC, a compound which is widely used as inhibitor of 
NF-κB activation. Unexpectedly, PDTC not only efficiently augmented TNFα-induced 
IL-8 (Fig.6A), but was also able to mediate release of IL-8 from DLD-1 cells as a 
single stimulus (Fig. 6A&B).  Under these experimental conditions induction of IL-8 
was not associated with cytotoxicity as assessed by quantitative analysis of DNA-
fragmentation, a common marker of apoptotic cell death. Treatment with the 
antioxidant acetylcystein did not mediate IL-8 expression (data not shown). Time-
course analysis revealed that PDTC induced a continous release of IL-8 from the 
cells that started after 4h of incubation. Most of the IL-8 was released between hour 8 
and 24 of stimulation. After 24h, a plateau of IL-8 concentration in the culture 
supernatants was reached (Fig.6C). 
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Fig. 6: (A) PDTC enhances TNFα-induced release of IL-8 from DLD-1 cells and likewise induces IL-8 
release as single stimulus. DLD-1 cells were incubated as unstimulated control (C), stimulated with 
TNFα (50 ng/ml), with PDTC (50 µM), or with TNFα (50 ng/ml) in combination with PDTC (50 µM) as 
indicated. After 24h, cell-free supernatants were assayed for IL-8 protein content by ELISA. Data are 
expressed as mean IL-8 concentrations ± SD (n = 4). **, p < 0.01 compared to untreated control; #, p 
< 0.05 compared to PDTC alone. 
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Fig. 6: (B,C) PDTC enhances TNFα-induced release of IL-8 from DLD-1 cells and likewise induces IL-
8 release as single stimulus. (B) DLD-1 cells were incubated as unstimulated control (C) or stimulated 
with the indicated concentrations of PDTC. After 8h, cell-free supernatants were assayed for IL-8 
protein content by ELISA. Data are expressed as mean IL-8 concentrations ± SD (n = 5). **, p < 0.01 
compared to untreated control. (C) DLD-1 cells were incubated as unstimulated control (closed circles) 
or stimulated with PDTC at 50 µM (open circles) or 200 µM (closed triangles). After the indicated time 
periods, cell-free supernatants were assayed for IL-8 protein content by ELISA. Data are expressed as 
mean IL-8 concentrations ± SD (n = 4). **, p < 0.01 compared to untreated control. 
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3.1.2  PDTC induces gene expression of IL-8, VEGF, and HO-1 in DLD-1 cells 
 
To further characterize PDTC-induced activation of DLD-1 cells, mRNA accumulation 
in response to the agent was investigated by RNase protection assay. In addition to 
IL-8, expression levels of two additional markers of cellular activation were 
determined: VEGF and HO-1 mRNA induction by PDTC was observed for all three 
genes investigated (Fig.7A-C). In order to confirm that upregulation of mRNA levels 
translated into protein expression, immunoblotting for HO-1 was performed. As 
shown in Fig.8, PDTC was a strong inducer of HO-1 in DLD-1 cells. As a positive 
control, DLD-1 cells were exposed to the nitric oxide donor GSNO, which was 
previously identified as mediator of HO-1 expression in rat renal mesangial cells 
(Sandau, K., et al. 1998) and human HaCaT keratinocytes (Wetzler C., et al. 2000). 
In contrast, stimulation of DLD-1 cells with the proinflammatory cytokine IL-1β was 
not sufficient to trigger induction of HO-1, which is in accord with a recent publication 
on regulation of HO-1 in HaCaT keratinocytes (Hanselmann, C., et al. 2001). 
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Fig. 7: (A) PDTC induces gene expression of IL-8, HO-1, and VEGF in DLD-1 cells. DLD-1 cells were 
incubated as unstimulated control (C) or stimulated with the indicated concentrations of PDTC for 8h. 
Thereafter, PDTC-induced IL-8 (A) mRNA accumulation was evaluated by RNase protection assay. 
One representative of three independently performed experiments is shown. Relative mRNA 
expression of this same experiment was quantified by PhosphoImager (Fuji) analysis of the 
radiolabeled gel. P denotes probe. 
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Fig. 7: (B,C) PDTC induces gene expression of IL-8, HO-1, and VEGF in DLD-1 cells. DLD-1 cells 
were incubated as unstimulated control or stimulated with the indicated concentrations of PDTC for 8h. 
Thereafter, PDTC-induced HO-1 (B), and VEGF (C) mRNA accumulation was evaluated by RNase 
protection assay. One representative of three independently performed experiments is shown. 
Relative mRNA expression of this same experiment was quantified by PhosphoImager (Fuji) analysis 
of the radiolabeled gel. P denotes probe. 
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Fig. 8: PDTC induces expression of HO-1 
protein in DLD-1 cells. DLD-1 cells were 
incubated as unstimulated control or 
stimulated with PDTC (50 µM), IL-1β (50 
ng/ml), or GSNO (500 µM) as indicated. 
After 8h, cells were harvested and 
homogenates were assayed for the 
presence of HO-1 protein by immunoblotting. 
 
 
3.1.3  PDTC upregulates IL-8 promotor activity in DLD-1 cells through an  
          NF-κB- and AP-1-dependent mechanism 
 
Gene induction of proteins such as intercellular adhesion molecule-1 (Munoz, C., et 
al. 1996 ), β2-integrin ( Aragones, J., et al. 1996), stromelysin (Yokoo, T. and 
Kitamura, M. et al. 1996), or glutathione S-transferase (Pinkus, R., et al. 1996) by 
PDTC is mediated by activation of the transcription factor AP-1. In keeping with these 
previous observations, we observed activation of AP-1 by PDTC by performing 
EMSA analysis (Fig.9A). In order to further investigate whether activation of the IL-8 
promotor was responsible for induction by PDTC, we transiently transfected the 
luciferase reporter gene under the control of a IL-8 promotor fragment (-558 to +98 
nt) (10) into DLD-1 cells. To evaluate a potential role for the AP-1 binding site (-127 
to –120 nt) in the IL-8 promotor, a site-directed mutation of this site was performed. In 
addition, a NF-κB mutant (-80 to –70) was generated in the same context of the IL-8 
promotor fragment (-558 to +98 nt). As a positive control for activation of the IL-8 
promotor, DLD-1 cells were stimulated with TNFα. As expected, TNFα induction of IL-
8 promotor activity was abbrogated by mutation of the NF-κB binding site in the IL-8 
promotor fragment (Fig.9C). In agreement with PDTC-induced IL-8 mRNA 
accumulation and protein release, promotor activity was significantly upregulated by 
the agent (Fig.9C).  Mutational analysis revealed that both, AP-1 and NF-κB were 
necassary for induction of IL-8 by PDTC (Fig.9C). It is well described that AP-1 and 
NF-κB can synergistically activate the IL-8 promotor (Roebuck, K.A. 1999). 
Therefore, we investigated the status of NF-κB activation in DLD-1 cells. A specific 
DNA-binding complex was strongly upregulated in response to TNFα, which was 
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used as a positive control in these experiments. In accord with a previous report 
(Kleinert, H., et al. 1998) ), constitutive NF-κB binding activity was observed in DLD-1 
cells. This constitutive NF-κB binding activity was still detectable in the presence of 
PDTC (Fig. 9B). It has been reported previously that PDTC is able to activate the 
transcription factor CCAAT/enhancer-binding protein β (C/EBPβ) (Chinery, R., et al. 
1997)). In addition, C/EBPβ has been identified as costimulus for optimal IL-8 
induction (Roebuck, K.A. 1999). To evaluate a potential role for the C/EBPβ binding 
site (-94 to -81 nt) in PDTC-induced IL-8 promotor activation, a site-directed mutation 
was performed, in the same context of the IL-8 promotor fragment (-558 to +98 nt). 
As shown in Fig. 9C, mutation of this site only partially reduced PDTC-induced IL-8 
promotor activity.  
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Fig. 9: (A,B) PDTC upregulates IL-8 
promotor activity in DLD-1 cells through 
an NF-κB- and AP-1-dependent 
mechanism. (A) Detection of PDTC-
induced AP-1 DNA binding activity in 
DLD-1 cells by EMSA analysis. DLD-1 
cells were incubated as unstimulated 
control (C), or stimulated with PDTC 
(200 µM) for the indicated time periods. 
Thereafter, nuclear extracts were 
prepared and EMSA analysis was 
performed using a 
32P-labeled AP-1 
consensus oligonucleotide. 
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Experiments were performed in the 
presence or absence of an anti-c-Jun 
antibody. The position of a supershifted 
band is indicated by an arrow. One 
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representative of three independently performed experiments is shown. (B) Detection of constitutive 
DNA binding activity of NF-κB in DLD-1 cells by EMSA. DLD-1 cells were incubated as unstimulated 
control (C), or stimulated with TNFα (50 ng/ml), or PDTC (50 µM) as indicated. After 1h, nuclear 
extracts were prepared and EMSA analysis was performed using a 
32P-labeled NF-κB consensus 
oligonucleotide, excess cold NF-κB consensus oligonucleotide, and excess cold mutated NF-κB 
consensus oligonucleotide as indicated. One representative of two independently performed 
experiments is shown. 
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Fig. 9: (C) PDTC upregulates IL-8 promotor activity in DLD-1 cells through an NF-κB- and AP-1-
dependent mechanism.  500 ng/well of β-Gal-constructs and 500 ng/well of one of the indicated 
luciferase-IL-8-promotor-constructs were used to transiently transfect DLD-1 cells. After 36h, 
transfected cells were either maintained as unstimulated control, or treated with PDTC (50 µM) (upper 
panel), or with TNFα (50 ng/ml) (lower panel) for additional 8h. Thereafter, cells were harvested and 
luciferase and β-Gal assays were performed, respectively. Data are expressed as fold induction of 
luciferase and are means ± SD (n = 5). *p < 0.05 compared to unstimulated control. A one-fold                                                                                                                            Results 
induction was assigned to the luciferase activity versus β-Gal activity in the respective unstimulated 
transfected DLD-1 cells.  
 
 
3.1.4 PDTC augments release of IL-8 from PBMC 
 
We also studied the effect of PDTC on IL-8 release from PBMC. As shown in 
Fig.10A, basal release of IL-8 from PBMC was significantly augmented by incubation 
with PDTC. In order to control for a potential LPS-contamination of the agent, 
experiments using the inhibitor of LPS action polymyxin B (PmxB) were performed. 
Upregulation of IL-8 release was not affected by pretreatment of control medium and 
PDTC with PmxB (final concentration: 2µg/ml) (Fig. 10A). Under the same 
experimental conditions LPS (10 ng/ml)-induced release of IL-8 from PBMC was 
efficiently abbrogated by pretreatment with PmxB (Fig.10B). LPS at 100 ng/ml did not 
mediate release of IL-8 from DLD-1 cells (data not shown).  
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Fig. 10: PDTC augments release of IL-8 from PBMC. PBMC were incubated as unstimulated control 
(A,B), or stimulated with PDTC (50 µM) (A), or with LPS (10 ng/ml) (B). Cells were also incubated as 
PmxB pretreated (final concentration: 2 µg/ml) control (A,B), or stimulated with PmxB pretreated (final 
concentration: 2 µg/ml) PDTC (50 µM) (A), or with PmxB pretreated (final concentration: 2 µg/ml) LPS 
(10 ng/ml) (B). After 24h, cell-free supernatants were determined by ELISA. Data are expressed as 
means  ± SEM (n = 4). *p < 0.05 compared to PmxB pretreated control; **p < 0.01 compared to 
untreated or PmxB pretreated control. 
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3.1.5 PDTC augments release and induces gene expression of IL-8 in U937 
 
We also studied the effect of PDTC on IL-8 release in U937 cells. As shown in 
Fig.11A-C, basal release of IL-8 from U937 was significantly augmented by 
incubation with PDTC. To further characterize PDTC-induced activation of U937 
cells, mRNA accumulation and IL-8 release in response to the agent was 
investigated by RT-PCR and ELISA, respectively. As shown in Fig. 11, expression 
and release of IL-8 was observed in U937 cells exposed to PDTC. 
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Fig. 11: (A-C) PDTC 
induces IL-8 release from 
U937 cells. (A-C) U937 
cells were incubated as 
unstimulated control, or 
stimulated with PDTC (10-
500 µM). After 4h,8h, and 
20h, cell-free supernatants 
were assayed for IL-8 
protein content by ELISA. 
Data are expressed as 
mean IL-8 concentrations 
± SD (n = 4). **p < 0.01 
compared to untreated 
control. 
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Fig. 11: (D,E) PDTC induces gene expression of IL-8 in U937 cells. (D, E) U937 cells were incubated 
as unstimulated control or stimulated with the indicated concentrations of PDTC for 8h (D) or 20h (E). 
Thereafter, PDTC-induced IL-8 mRNA accumulation was evaluated by RT-PCR. One representative of 
three independently performed experiments is shown. 
 
 
3.2.1 Induction of iNOS  in DLD-1 colon carcinoma cells 
 
Induction of iNOS protein and activity has been observed in colorectal cancer (Ambs, 
S., 1998 and 1999; Szaleczky, E., et al. 2000)  and is supposed to be mediated by 
inflammatory cytokines which are expressed at the tumor site, among others IL-Iβ, 
TNFα, and IFNγ (Csiszar A., et al. 2001; Numata A, et al. 1991; Yoshimi N., et al. 
1994) . Accordingly, activation of DLD-1 colon carcinoma cells by exogenous IL- 1 
β/IFNγ resulted in strong expression of iNOS (Fig. 12).  
 
73                                                                                                                            Results 
 
-iNOS
control  IL-1   IFN  IFN
                                    IL-1
βγ   γ
β
11 6kD-
97kD-
66kD-
200kD-
A
 
  Fig. 12 Confluent DLD-1 
cells were stimulated for 48h 
with IL-1β (50 ng/ml), IFN-γ 
(20 ng/ml), with IL-1β (50 
ng/ml) plus IFNγ (20 ng/ml), 
or incubated as unstimulated 
control. Thereafter, iNOS 
protein expression was 
investigated by immunoblot 
analysis. One representative 
of two independently 
performed experiments is 
shown.  
 
 
3.2.2 Nitric oxide amplifies expression of proangiogenic IL-8 and VEGF in 
         DLD-1 colon carcinoma cells. 
 
IL-8 has been recognized as an important proangiogenic mediator ( Belperio, J.A., et 
al. 2000) and a proliferative stimulus for colon carcinoma cells (Miyamoto, M. et al. 
1998). Thus, effects of exogenous NO on the production of IL-8 by DLD-1 cells were 
investigated. As shown in Fig.13, IL-1β potently activated release of IL-8. 
Coincubation with IL-1β/IFNγ did not further enhance IL-8 production. Moreover, IL-8 
was not inducible by IFNγ alone. Thus, IL-8 is primarily an IL1 β-dependent gene in 
this experimental system. The role of NO in regulating gene expression in these cells 
was investigated by preincubation of cells with the NO-donor DETA-NO which 
spontaneously releases NO with a characteristically long half-life of 16.5h (Mühl H. et 
al., 2000). DETA-NO significantly augmented release of IL- 8 by DLD- 1 cells 
stimulated either with IL- 1 β alone or with the combination IL- 1 β/IFNγ. Augmented 
secretion of IL-8 protein under the influence of NO was paralleled by upregulation of 
IL-8 mRNA steady-state levels (Fig.13B). NO also significantly increased low level 
basal release of IL-8 protein (Fig.13C) and expression of mRNA as detected by 
RT-PCR analysis (data not shown). In accord with previous data we confirm that 
DLD-1 cells constitutively produce VEGF (Okada, F., et al. 1998). Basal expression 
of VEGF was significantly upregulated by coincubation with NO (Fig. 14). 
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Fig. 13: (A-C) NO enhances expression and release of IL-8 from DLD-1 colon carcinoma cells. (A) 
DLD-1 cells were incubated as unstimulated control or with DETA-NO (NO, 1 mM). After 16h, 
IL- 1β  (50 ng/ml), IFNγ (10 ng/ml) or IL- 1β plus IFNγ were added as indicated. Following an additional 
8h incubation period, release of IL-8 was determined by ELISA. Mean IL-8 concentrations ± SD are 
shown (n = 6). **, p < 0.01 compared to unstimulated control; ##, p < 0.01 compared to stimulation 
with IL-1β/IFNγ alone. (B) DLD-1 cells were incubated with control culture medium (C) or with 
DETA-NO (NO, 1 mM). After 16h, IL-1ß (50 ng/ml)/IFNγ (10 ng/ml) were added. Following an 
additional 8h incubation period, expression of IL-8 was determined by RNase protection assay. One 
representative of three independently performed experiments is shown. (C) NO as a single stimulus 
mediates expression of IL-8. DLD-1 cells were stimulated with the indicated concentrations of 
DETA-NO. After 25h, expression of IL-8 was determined by ELISA (C). Data are expressed as mean 
IL-8 concentrations ± SD (n6). **, p < 0.01 compared to unstimulated control. 
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Fig. 14: (A,B) NO mediates induction of VEGF in DLD-1 cells. DLD-1 cells were stimulated for 24h 
with DETA-NO at 1 mM (A) or with DETA-NO in the indicated concentrations (B). Thereafter, release 
of VEGF was determined by ELISA (A). Data are expressed as mean VEGF concentrations ± SD (n = 
6). *, p < 0.05 compared to unstimulated control. mRNA expression of VEGF was evaluated by RNase 
protection assay (B).  
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3.2.3 Nitric oxide suppresses IL-1β/IFNγ-induced expression of the   
        antiangiogenic chemokines IP-10 and MIG as well as expression of iNOS 
 
Among the chemokines expressed by IL-1β/IFNγ-activated DLD-1 colon carcinoma 
cells are the tumor suppressive molecules IP-10 and MIG. In contrast to IL-8, 
expression of these two mediators required cellular activation by IFNγ. Moreover, a  
coincubation with IL1β/IFNγ was necessary to detect IP-10 production after an 8h 
incubation period (Fig.15A). The observed strong synergistic effect between IL-1β 
and IFNγ concerning IP-10 release and a 8h lag period in cells stimulated with IFNγ 
alone (Fig.15A) agrees with recent data on human visceral epithelial cells (glomerular 
podocytes) (Romagnani P., et al. 2002). Preincubation of DLD-1 cells with DETA-NO 
potently reduced expression of IP-10 (Fig.15B) and MIG (Fig.15C). In addition, we 
also investigated regulation of iNOS by NO. Like IP-10 and MIG, iNOS is an 
IFNγ-dependent gene in DLD-1 cells (Fig. 12). As shown in Fig. 16, preincubation 
with NO reduced IL- 1 β/IFNγ-mediated mRNA (A) and protein expression of iNOS 
(B). This observation contrasts with regulatory actions of NO on iNOS expression in 
renal mesangial cells. In this cellular system iNOS is inducible by IL-1β alone. Similar 
to data on IL-1β-dependent IL-8 regulation in DLD-1 cells, NO enhanced 
IL-1β-induced iNOS expression in mesangial cells (Fig.16C), which corrobates 
previous data (Mühl H., and Pfeilschifter J., 1995). 
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Fig. 15: (A-C) NO suppresses IL-1β/IFNγ-induced IP-10 and MIG expression. (A) DLD-1 cells were 
kept as unstimulated control or incubated with IL-1β (50 ng/ml), with IFNγ (10 ng/ml), or with 
IL-1β/IFNγ. After 8h, release of IP-10 protein (left panel) and expression of IP-10 mRNA (right panel) 
were determined by ELISA and Northern blot analysis, respectively. Protein levels are expressed as 
mean IP-10 concentrations ± SD (n = 4). **, p < 0.01 compared to unstimulated control. One 
representative of three independently performed Northern blot experiments is shown. (B) DLD-1 cells 
were incubated as unstimulated control or with DETA-NO (1 mM). After 16h, IL-1β (50 ng/ml)/IFNγ (10 
ng/ml) was added as indicated. Following an additional 8h incubation period, release of IP-10 protein 
(left panel) and expression of IP-10 mRNA (right panel) were determined by ELISA and Northern-blot 
analysis, respectively. Protein levels are expressed as mean IP-10 concentrations ± SD (n = 6). **, p < 
0.01 compared to unstimulated control; #, p < 0.01 compared to IL-lβ/IFNγ alone. One representative 
of three independently performed Northern blot experiments is shown. (C, left panel) DLD- 1 cells 
were kept as unstimulated control or incubated with IL- 1β (50 ng/ml), with IFNγ (10 ng/ml), and with 
IL-Iβ/IFNγ. After 8h, expression of MIG mRNA was determined by Northern-blot analysis. One 
representative of three independently performed Northern-blot experiments is shown. (C, right panel) 
DLD-1 cells were incubated as unstimulated control or with DETA-NO (1 mM). After 16h, IL- 1β (50 
ng/ml)/IFNg (10 ng/ml) was added as indicated. Following an additional 8h incubation period, 
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expression of MIG mRNA was detennined by Northern-blot analysis. One representative of three 
independently performed Northern-blot experiments is shown. 
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Fig. 16: (A-C) NO differentially regulates IFNγ- and IL-1β-driven expression of iNOS. DLD-1 cells were 
incubated as unstimulated control or with DETA-NO (NO, 1 mM). After 16h, IL-1β (50 ng/ml)/IFNγ (10 
ng/ml) was added. Following an additional 24h incubation period expression of iNOS was determined 
by RNase protection assay (A) and immunoblot analysis (B), respectively. One representative of three 
independently performed RNase protection assays and immunoblot experiments are shown. (C) Rat 
renal mesangial cells were kept as unstimulated control, or stimulated for 24h with IL-1β (50 ng/ml) 
alone, or in combination with DETA-NO (NO, 1 mM). Thereafter, iNOS expression was investigated by 
immunoblot analysis (C). 
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4 Discussion 
4.1 Aim of the Study 
We investigated the expression of parameters of angiogenesis in activated DLD-1 
colon carcinoma cells. In order to activate these cells two stimulatory signals were 
used:  
In the first part of the study cells were exposed to PDTC which is an AP-1 activating 
agent that has been proposed as a treatment option of colorectal cancer in 
combination with chemotherapeutic drugs. 
In the second part we studied effects of NO which is an immunmodulatory radical that 
is endogenously produced in the microenvironment of human colon cancer. 
 
 
4.2 The role of chemokines in cancer 
Cancer is a devastating disease for which standard therapy frequently fails. An 
estimated 5.2 million people die each year from cancer-related deaths around the 
world. Novel therapies that gained popularity because of recent advances are anti-
angiogenesis drugs and tumor vaccines (Parkin, D.M, et al. 1999). Chemokines are 
particularly promising molecules because they have proved useful as both anti-
angiogenic agents and critical determinants for successful tumor vaccine 
development in preclinical animal models (Belperio, J.A. et al. 2000; Fushimi, T. et al. 
2000; Sharma, S. et al. 2000) .  
Chemokines, as with other cytokines, are meant to function locally, and systemic 
delivery could result in unwanted side effects and toxicity. One promising avenue is 
the delivery of chemokines by conventional gene therapy vectors, which has been 
successfully employed by several investigators in murine models (Addison, C.L. et al. 
2000; Fushimi, T. et al. 2000; Narvaiza, I. et al. 2000;  Emtage, P.C. et al. 1999). An 
advantage of using chemokines is that, as opposed to tumor suppressor or death 
genes, not necessarily every tumor cell has to be transduced. Thus, if a proportion of 
tumor cells secrete an angiostatic molecule, the balance of angiogenic factors in the 
tumor environment might be altered sufficiently to prevent neovascularisation and 
further cancer growth. This concept is even more apparent for the development of 
tumor vaccines, which initially requires interaction between only a subset of tumor 
cells, antigen-presenting cells and T cells. 
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Figure 17: The balance 
of angiogenic and 
angiostatic chemokines 
in the tumor 
microenvironment can 
determine tumor survival. 
Chemokines can 
stimulate or inhibit 
proliferation and 
chemotaxis of 
endothelial cells of the 
blood vessels that serve 
a tumor. If a tumor 
secretes excess of 
angiogenic chemokines 
[e.g. interleukin 8 (IL-8)] 
angiogenesis is 
stimulated, leading to 
new blood vessel 
formation and continued 
tumor growth. An excess 
of angiostatic 
chemokines [e.g. 
interferon-γ-inducible 
protein 10 (IP-10)] in the 
tumor microenvironment 
inhibits 
neovascularisation, 
leading to tumor necrosis 
and regression (adapted 
from Mitchell J. Frederick 
and Gary L. Clayman, 
2001). 
 
 
4.2.1 IL-8, VEGF and HO-1 in angiogenesis 
IL-8 and VEGF are two mediators of angiogenesis and tumor progression which are 
coexpressed in a variety of human tumors, including colorectal cancer (Fox, S.H.,  
1998; Bancroft, C.C.,2001). IL-8 was the first chemokine discovered to stimulate 
endothelial cell chemotaxis, proliferation and angiogenesis in vivo (Koch, A.E. et al. 
1992). Many tumors overexpress IL-8, compared with their surrounding non-
malignant tissue. IL-8 is an autocrine growth factor for certain melanomas 
(Schadendorf, D. et al. 1993) as well as tumor cell lines derived from cancers of the 
colon, stomach, liver, pancreas and skin (Fujisawa, N. et al. 2000; Brew, R. et al. 
2000; Miyamoto, M. et al. 1998; Metzner, B. et al. 1999). In biopsy tissue from 
ovarian carcinomas, neuroblastomas and squamous cell carcinomas of the head and 
neck, both IL-8 and its receptor are expressed by cancerous cells, suggesting that IL-
8 could also function in an autocrine factor for these tumors (Ivarsson, K. et al. 2000; 
Ferrer, F.A. et al. 2000; Richards, B.L. et al. 1997). The autocrine function of  IL-8 
illustrates the pleiotropism of chemokines, as these particular molecules not only 
stimulate tumors to multiply, but also recruit endothelial cells in vivo to ensure that 
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tumors develop an adequate vasculature as they grow. IL-8 is perhaps one of the 
most ideal tumor growth factors (Mitchell J.F., et al. 2001). In many cell types the 
synthesis of IL-8 is strongly induced by IL-1β and/or TNF-α. IL-8, IL-1β, and TNF-α 
are known collectively as major proinflammatory cytokines because they accelerate 
inflammation and also regulate inflammatory reactions either directly or by their ability 
to induce the synthesis of cellular adhesion molecules or other cytokines in certain 
cell types. The net effect of an inflammatory response is determined by the balance 
between proinflammatory cytokines and antiinflammatory cytokines (see also 
introduction). IL-8 is constitutively produced by various carcinoma cells and this 
synthesis may be related to the elevation of serum IL-8 in patients with hepatocellular 
carcinoma (Zwahlen, R.,  et al. 1993).      
One of the most important growth and survival factors for the endothelium is vascular 
endothelial growth factor (VEGF) (Ferrara, N. et al. 1999). VEGF induces 
angiogenesis and endothelial cell proliferation and plays an important role in 
regulating vasculogenesis. VEGF is a heparin-binding glycoprotein that is secreted 
as a homodimer (Houck, K.A. et al. 1992; Park, J.E. et al. 1993; Houck, K.A. et al. 
1991). Most types of cells, but usually not endothelial cells themselves, secrete 
VEGF. VEGF has been renamed to VEGF-A, following the identification of several 
VEGF-related factors (VEGF-B, VEGF-C, VEGF-D, VEGF-E ). VEGF is a 
homodimeric heavily glycosylated protein of 46-48 kDa (24 kDa subunits). However, 
glycosylation is not required, for biological activity. The subunits of VEGF are linked 
by disulphide bonds. The human factor occurs in several molecular variants of 121 
(VEGF-121 ), 165 (VEGF-165 ), 183 ( VEGF-183 ), 189 ( VEGF-189 ) and 206 ( 
VEGF-206 ) amino acids, arising by alternative splicing of the mRNA. Another variant 
has been designated VEGF-C . Other VEGF-related factors are e.g. VEGF-B , which 
forms heterodimers with VEGF-A, and VEGF-C . Since it is a potent regulator of 
vascular permability, VEGF was formaly also known as vascular permability factor 
(Dvorak, H.F. et al. 1999). In addition, VEGF causes vasodilatation, partly through 
stimulation of constitutive nitric oxide synthase in endothelial cells (Yang, R. et al. 
1996). VEGF can also stimulate cell migration and inhibit apoptosis (Alon, T. et al. 
1995). Several splice variants of VEGF-A have heparin-binding domains, which help 
anchor them in the extracellular matrix and facilitate presentation to VEGF receptors. 
VEGF-A transcription is potentiated in response to hypoxia. The transcription factors 
which are involved are hypoxia inducible factor-1α (HIF-1α) and HIF-2α. These are 
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degraded by the proteasome pathway in normoxia but stabilized in hypoxia (Kallio, 
P.J. et al. 1999). HIF-1α and HIF-2 α heterodimerize with the aryl hydrocarbon 
nuclear translocator (ARNT) in the nucleus and bind the VEGF promoter/enhancer. 
This is a key pathway operating in most types of cells. VEGF transcription in 
normoxia is activated by many oncogenes including H-ras and several 
transmembrane tyrosine kinases such as the epidermal growth factor receptor and 
erbB2 (Arbiser, J.L. et al. 1997; Okada, F. et al. 1998; Petit, A.M. et al. 1997). 
Together, hypoxia and oncogenic activation, may account for a marked upregulation 
of VEGF-A in tumors compared to normal tissues, a process that is of prognostic 
relevance in clinical practice (Gaspeirini, F. et al. 1997). VEGF can be detected in 
serum samples of cancer patients (Banks, R.E. et al. 1998). Platelets release VEGF 
upon aggregation and may be a major source of VEGF delivery to tumors (Pinedo, 
H.M. et al. (1998). Several studies have shown that high serum levels of VEGF and 
poor prognosis in cancer patients may be correlated with an elevated platelet count 
(O’Byrne, K.J. et al. 1999). Many tumors release cytokines that can stimulate the 
production of megakaryocytes in the bone marrow and elevate the platelet count. 
This can result in an indirect increase of VEGF delivery to tumors (Salgado, R. et al. 
1999). Besides tumorgenesis VEGF is implicated in several other pathological 
conditions associated with enhanced angiogenesis. For example, VEGF plays a role 
in psoriasis, diabetic retinopathy, and rheumatoid arthritis (Koch, A.E. et al. 1994; 
Ferrara, N. et al. 1998). Direct demonstration of the importance of VEGF in tumor 
growth has been achieved by using dominant negative VEGF receptors (Millauer, B. 
et al. 1996)  and neutralizing antibodies for VEGF (Witte, L. et al. 1998) or VEGF 
receptors. Interference with VEGF function has therefore become of major interest for 
drug development with the aim to block angiogenesis. These approaches include 
antagonists of VEGF or its receptors, selective VEGF receptor tyrosine kinase 
inhibitors (Piossek C., et al. 1999), targeting of drugs and toxins to VEGF receptors 
(Saleh, M. et al. 1996), as well as hypoxia driven gene therapy targeting VEGF or the 
VEGF signaling pathway (Dachs G.U., et al, 1997).  
HO-1 is a 32-kDa protein that is inducible by numerous stimuli. HO-1 catalyzes the 
first and rate-limiting step in the degradation of heme. Via oxidation, HO-1 cleaves 
the α-meso carbon bridge of β-type heme molecules to yield equimolar quantities of 
biliverdin IXa, CO, and free iron. Biliverdin is subsequently converted to bilirubin via 
the action of biliverdin reductase, and free iron is promptly sequestered into ferritin. 
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To date, three isoforms (HO-1, HO-2, and HO-3) that catalyze this reaction have 
been identified  (Abraham, N.G.,  et al. 1987; Maines, M.D. 1988; Mc Coubrey, W.K., 
et al. 1992;  Mc Coubrey, W.K., et al. 1997). Although heme is the typical HO-1 
inducer, several studies demonstrated that HO enzyme activity could also be 
stimulated by a variety of nonheme products including ultraviolett irradiation, LPS, 
heavy metals, NO and oxidants such as hydrogen peroxide (Keyse and Tyrell, 1987; 
Maeshima et al., 1996; Vile and Tyrell, 1993). One common feature of these inducers 
is their capacity to generate reactive oxygen species.  HO-1 can function as a 
cytoprotective molecule against oxidative stress. Indeed, ample evidence currently 
supports the notion that HO-1 serves to provide potent cytoprotective  and 
antiinflammatory effects in many in vitro and in vivo models of oxidant-induced 
cellular and tissue injury.  
As for IL-8 and VEGF, induction and activity of HO-1 has been associated with 
growth of solid tumors (Doi, K., et al. 1999 ; Nishie, A., et al. 1999). 
 
 
4.3 The role of PDTC as drug in clinical trials and its mode of action 
 
Primarily due to its capability of inducing apoptosis in certain cancer cells, use of 
PDTC as an anticancer drug has been proposed (Chinery, R., 1997; Bach, S.P.2000;  
Della Ragione, F. 2000). PDTC is a member of the dithiocarbamate family, well 
known for its ability to bind free or protein-bound metal (Orrenius, S., et al. 1996). 
Dithiocarbamates exert both antioxidant and prooxidant effects in cells. Their 
antioxidant behaviour includes eliminating hydrogen peroxide (Mankhetkorn, S.,  et 
al. 1994) and the scavenging of superoxide radicals (Mankhetkorn, S.,  et al. 1994), 
peroxynitrite ( Liu, J., et al. 1996), hydroxyl radicals ( Liu, J., et al. 1996), as well as  
the peroxyl radicals (Bartoli, G. M., et al. 1993; Zanocco, A. L., et al. 1989). The 
reaction of dithiocarbamates with reactive oxygen and nitrogen species generates 
dithiocarbamate thiyl radicals which ultimately dimerize to form thiuram disulphides 
(Mankhetkorn, S.,  et al. 1994; Liu, J., et al. 1996; Zanocco, A. L., et al. 1989), the 
oxidized form of dithiocarbamates. Thiuram disulphides are responsible for much of 
the prooxidant characteristics of dithiocarbamates. PDTC thus can potently oxidize 
GSH (reduced glutathione) a cellular protectant, and protein thiols (Orrenius, S., et al. 
1996; Hosni, M. et al. 1992; Nobel, C. S. I., et al. 1995). In the analysis of 
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dithiocarbamate action, the antioxidant behaviour of these agents has been more 
often acknowledged, with less appreciation for their prooxidant character. For 
example, although inhibition of NFκB activation by PDTC has often been attributed to 
its radical-scavenging properties (Schreck, R., et al 1992;  Meyer, M., et al. 1993), it 
has recently been demonstrated that PDTC may exert its inhibitory effect on NFκB 
via direct oxidation of critical thiols located in this transcription factor  (Brennan, P. 
and O'Neill, L. A. J. 1995; Brennan, P. and O'Neill, L. A. J. 1996). Recent evidence 
suggests, that the reactive oxygen species (ROS) model of NFκB activation may be 
restricted to certain cell types and that this activation pathway may not be required for 
the stimulation of NFκB by IL1-β and TNFα. The prooxidant consequences of 
dithiocarbamate action, have recently been highlighted with respect to their infuence 
on apoptosis (Orrenius, S., et al. 1996;  Nobel, C. S. I., 1997). PDTC has become 
more and more of interest  in relation to cancer therapy particularly in combination 
with classical cytostatic agents. In preclinical studies (Chinery, R., et al. 1997), 
antioxidants have been tested as potential therapeutic agents for treatment of 
colorectal cancer. In these studies, it has been found that PDTC can induce growth 
arrest, activation of p21
WAF/CIP1 (WAF1 denotes wild-type p53-activated fragment-1 
and CIP1 denotes cyclin-dependent kinase-interacting protein-1) and apoptosis in 
colorectal cancer cells in vitro. Moreover, PDTC can induce regression of human 
colon cancer tumors in nude mice when given in combination with 5-FU 
(Beauchamp,R.D., et al 1996). Actions of PDTC on cells also include potent 
activation of the transcription factor AP-1 (Yokoo, et al 1995), which is involved in 
cellular proliferation, transformation, and death (Shaulian and Karin, 2002). PDTC  
enhances the DNA-binding activity of AP-1, as well as c-fos and c-jun mRNA levels 
(Munoz C. et al. 1996).  AP-1 is not a single protein, they belong to a group of dimeric 
basic region-leucine zipper (bZIP) proteins that belong to the Jun/Fos subfamilies. 
The growth-promoting activity of AP-1 is mediated by c-Jun. c-Jun mediates  
repression of tumor suppressors, as well as upregulation of positive cell cycle 
regulators. Mostly, c-Jun is a positive regulator of cell proliferation, whereas JunB has 
the converse effect (Shaulian and Karin, 2002).  The induction of AP-1 by 
proinflammatory cytokines and stressors like PDTC is mostly mediated by 
phosphorylation of tyrosine kinases (Yokoo T. and Kitamura M. 1996).  
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4.4 Effects of PDTC on the expression of IL-8,   
      VEGF, and HO-1 
 
We investigated effects of PDTC on the expression of IL-8, VEGF, and HO-1. 
In this work we report that expression of this particular set of genes is induced by 
PDTC  in human DLD-1 colon carcinoma cells. In contrast, treatment with the 
antioxidant acetylcysteine did not mediate IL-8 expression. Induction of HO-1 by 
PDTC agrees with recent data from rat aortic smooth muscle cells (Hartsfield, C.L., et 
al, 1998). In addition, we demonstrate that PDTC can efficiently enhance TNFα-
mediated release of IL-8 from DLD-1 cells. At first sight these observations appear 
unexpected as IL-8 is an NF-κB dependent gene (Roebuck, K.A. 1999) and NF-κB 
activation can be inhibited significantly by treatment with PDTC in certain cell types 
(Schreck, R., et al. 1992; Eberhardt, W., et al. 1994). However, in human colon 
carcinoma cells inhibition of NF-κB activation by PDTC was not observed (Chinery, 
R., et al. 1997; Hellin, A.C., et al 1998). In leukemic promonocytic U937 cells, PDTC 
not only was unable to inhibit TNFα-induced NF-κB activation, but actually enhanced 
TNFα-mediated κB-dependent gene induction (Watanabe, K., et al. 1999). Moreover, 
TNFα-induced NF-κB binding activity could only be partially suppressed (50% 
inhibition) by PDTC at 100 µM in SW620 human colon carcinoma cells (Wahl, C., et 
al. 1998). In keeping with previous reports, we confirm constitutive NF-κB binding 
activity in human colon carcinoma cells  as seen in DLD-1 cells (see also results 
Fig.4B; Kleinert, H., et al. 1998) or SW48 cells (Lind, D.S., et al. 2001). This 
constitutive activity was not reduced by treatment with PDTC in DLD-1cells. 
Molecular cooperation particularly between the transcription factors NF-κB and AP-1 
has been identified as an essential prerequisite for optimal gene induction of IL-8 in 
epithelial cells (Mastronarde, J.G., et al. 1998). As already mentioned PDTC is a well 
characterized activator of AP-1 (Munoz, C., et al. 1996;  Aragones, J.,et al. 1996; 
Yokoo, T. and Kitamura, M. 1996; Pinkus, R., et al. 1996; Hartsfield, C.L.,et al. 1998; 
Meyer, M., et al. 1993). In the present study we were able to confirm activation of AP-
1 by PDTC using EMSA analysis. We investigated also the importance of the binding 
sites for AP-1 and NF-κB with regard to PDTC-induced IL-8 by mutational analysis of 
the IL-8 promotor. The NF-κB- (-80 to -70 nt) as well as the AP-1-binding site (-127 to 
-120 nt) ( Roebuck, K.A. (1999) both turned out to be necessary for PDTC-induced 
IL-8.  
86                                                                                                                     Discussion 
  PDTC/H2O2 
RSV  NAC 
 
Figure 18: Schematic arrangement of putative transcription factor binding sites in the IL-8 promotor  
 
These data imply that PDTC-induced AP-1 cooperates with constitutive NF-κB 
activity in DLD-1 cells which then drive synergistic expression of IL-8. In addition, 
mutational analysis of the C/EBPβ binding site (-94 to –81 nt) suggested that PDTC-
induced activation of C/EBPβ (Chinery, R., et al. 1997) contributes to a certain 
degree to IL-8 promotor activation by this agent. This observation is in keeping with 
previous reports demonstrating the capability of C/EBPβ to enhance NF-κB 
dependent IL-8 expression (Stein, B. and Baldwin, A.S. Jr. 1993). 
 
Induction of IL-8 by PDTC was not restricted to colon carcinoma cells but was also 
detectable in human PBMC, where monocytes are regarded as the major source of 
IL-8 (DeForge, L.E., et al. 1992). Accordingly, PDTC has been shown previously to 
activate AP-1 in monocytic cells (Watanabe, K., et al. 1999). In the present study, 
PBMC were isolated from whole blood by density separation over a Ficoll-Hypaque 
gradient, which is standard methodology. This procedure is unevitably associated 
with activation of PBMC, as shown by induction of TNFα mRNA expression (Hartel, 
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C., et al. 2001), a process likely to be mediated by activation of NF-κB. Therefore, 
upregulation of IL-8 in PBMC is in keeping with the hypothesis that PDTC-stimulated 
AP-1 mediates IL-8 production in preactivated cells. Augmentation of IL-8 release 
from PBMC by PDTC was however modest compared to inflammatory stimuli such 
as IL-1β or LPS (Fig.5). The present observation that IL-8 can be induced by PDTC 
as a single stimulus appears to be of particular significance in the context of 
transformed colon carcinoma cells in which NF-κB is not (Chinery, R., et al. 1997; 
Hellin, A.C., et al. 1998;  present data) or only partially (Wahl, C., et al. 1998) 
modulated by PDTC. Thus our data do not necessarily contradict the 
antiinflammatory potential of PDTC ( Lauzurica, P., et al.1999;  Munoz, C., et al. 
1996). 
Lately it has been reported that IL-1β-induced IL-8 secretion in the human intestinal 
cell line HT-29 could be attenuated by PDTC in a dose dependent manner (Nemeth 
ZH, et al. 2003). Furthermore, accumulation of IL-8 mRNA was suppressed. In these 
cells activation of IL-8 was inhibited because IL-1β-induced NFκB DNA binding and 
NFκB-dependent transcriptional activity was potently suppressed by PDTC. In 
contrary to DLD-1 cells, HT-29 cells have a very low basal level of NFκB activation. 
Thus, the status of NFκB in DLD-1 cells is quite different from that in HT-29 cells. 
Again, in contrast to the situation in DLD-1 cells, NFκB binding was potently 
upregulated by IL-1β in HT-29 cells and this activation was inhibited by PDTC.  
Consequently, subsequent IL-1β-induced IL-8 was inhibited by PDTC in these cells. 
In conclusion, these results from the HT-29 study concure with our concept that the 
state of cellular NFκB activation in a given cell type determines PDTC actions on 
these cells. In DLD-1 cells PDTC-induced activation of AP-1 synergizes with 
constitutive NFκB for IL-8 production. In HT-29 cells, NFκB is not constitutively 
activated and PDTC-induced AP-1 alone is not sufficient to trigger IL-8 expression.  
 
 We did not further investigate the molecular basis of PDTC-induced VEGF and HO-1 
gene activation. However, similar to IL-8, expression of VEGF (Bancroft, C.C.,  et al. 
2001;  Damert, A., et al. 1997) and HO-1 (Alam, J. and Den, Z. 1992) can be induced 
by activation of AP-1 in cancer cells. AP-1 in particular mediates PDTC-induced HO-
1 gene induction in the murine transformed macrophage-like cell line RAW 264.7 
(Hartsfield, C.L.,  et al. 1998). 
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Recently, it has been reported that NF-κB binding activity is augmented in human 
colorectal cancer (Lind, D.S., et al. 2001). The present data imply that exposure of 
these tumor tissues to PDTC during chemotherapeutic intervention may mediate 
expression of proangiogenic IL-8 and VEGF, as well as HO-1 in colon carcinoma 
cells. A cellular response that could adversely affect the efficacy of PDTC in cancer 
therapy.  
 
 
4.5 Effects of NO on the expression of IL-8, VEGF, MIG, and IP-10 
 
Upregulation of iNOS protein and activity has been observed in a variety of human 
cancers e.g. colorectal cancer, breast cancer (Thomsen, L.L., et al. 1995), in tumors 
of the central nervous system (Cobbs, C.S.,et al.1995), in prostate cancer (Klotz, T., 
et al. 1998), in lung cancer (Liu, C.Y., et al. 1998), in ovarian cancer (Thomsen, 
L.L.,et al. 1998), as well as in melanomas (Tschugguel, W., et al.1999), and head 
and neck cancer (Gallo 0., et al. 1998). Cell culture experiments suggest an 
antiproliferative role of NO in colon carcinoma cells (Buga, G.M., et al 1998). 
Furthermore, apoptosis of cancer cells driven by high levels of NO is a well described 
phenomenon (Cui S., et al. 1994). However, analysis of iNOS expression in human 
tumor tissues and murine tumor models may point to a different role of NO in tumor 
biology. It has been shown that expression of iNOS in human colon cancer tissues is 
positively correlated with the frequency of mutations in the p53 tumor suppressor 
gene. This implies that NO provides a significant selection pressure for nonfunctional 
p53, a mechanism that may ultimately promote tumor growth (Ambs, S., et al. 1999). 
lt has also been reported that compared to wild-type cells, overexpression of iNOS in 
DLD-1 cells results in enhanced tumor growth when these cells are injected into nude 
mice. Tumors derived from these iNOS overexpressing carcinoma cells appear 
markedly more vascularized (Jenkins, D.C., et al 1995). Similar observations have 
been reported using Calu-6 lung carcinoma cells (Ambs, S., et al. 1998). Notably, 
DLD-1 cells (Kagawa, S., et al. 1997) and Calu-6 (Ambs, S., et al. 1998) cells do not 
express wild-type p53 since NO can mediate apoptosis via p53 (Messmer U., et al, 
1994) This lack of wild-type p53 appears to be an important determinant of NO action 
in these murine models of tumor growth (Ambs, S., et al. 1998). NO-mediated tumor 
promotion agrees with a report investigating expression of iNOS in human head and 
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neck cancer (Gallo, 0., et al. 1998). In that study expression of iNOS is proposed as a 
marker of tumor progression which closely correlates with  angiogenesis and tumor 
vascularization. A similar association of iNOS, angiogenesis and tumor progression 
has been observed in a model of mammary cancer (Jadeski, L.C., and Lala, P.K. 
1999). As tumor angiogenesis is recognized as a chief parameter determining tumor 
growth (Kerbel, R.S. 2000) , we investigated effects of NO on DLD-1 cells with 
respect to expression of four well documented regulators of angiogenesis, namely 
angiogenic VEGF (Holash, J., et al. 1999) and IL-8 (Koch, A.E., et al. 1992) as well 
as angiostatic IP-10 (Luster, A.D.,  et al. 1995) and MIG (Addison C.L., et al. 2000).  
Here, we report that IL-1β-dependent production of IL-8 in DLD-1 cells is significantly 
increased by coincubation with NO. Upregulation of IL-8 release by NO agrees with 
reports on IL-8 regulation in human mesangial cells (Brown, Z., et al. 1993), 
endothelial cells (Villarete L.H., and Remick D.G. (1995), keratinocytes (Wetzler C., 
et al. 2000), and monocytes (Mühl H., et al. 2000). It is interesting to note that IL-8 
not only is as active as VEGF in mediating angiogenesis (Koch, A.E., et al. 1992), but 
is also a growth factor for colon carcinoma cells. (Brew R., et al. 2000; Li A., et al. 
2001). In accord with previous data on glioblastoma cells and hepatocellular 
carcinoma cells (Chin, K., et al. 1997), constitutive production of VEGF in DLD-1 cells 
was enhanced by NO. Likewise, overexpression of iNOS can mediate amplification of 
VEGF production (Jozkowicz A., et al. 2001)). Moreover, reduced  VEGF has been 
detected in tumors of iNOS deficient mice (Kisley L.R., et al. 2002). Contrary to these 
promotors of tumor growth, we observed that expression of the angiostatic 
chemokines IP-10 and MIG is efficiently suppressed under the influence of NO. A 
similar NO-induced downregulation of IP-10 and MIG expression has been reported 
in human vascular endothelial cells and visceral epithelial cells (glomerular 
podocytes) (Mach, F., et al. 1999), Thomsen, L.L., et al. 1995). 
Suppression of IP-10 and MIG is likely a key event that is mediated by NO in the 
tumor microenvironment. Both CXC chemokines bind to the same receptor (CXCR3) 
and both are often coexpressed as shown for EBV-positive lymphomatoid 
granulomatosis and nasal-type T cell/NK cell lymphomas. In these cancerous tissues, 
high levels of MIG and IP-10 are associated with necrosis and vascular damage 
(Teruya Feldstein J. et al, 1997). IP-10 and MIG are chemoattractant for activated T 
cells. Actually, strong expression of MIG has been detected in human malignant 
melanomas in areas of heavy T cell infiltration. Evidence suggests that MIG is critical 
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for control of melanoma growth (Kunz M., et al. 1999). The relevance of these two 
chemokines is further underscored by the observation that injection of MIG into 
Burkitt tumors grown in nude mice causes tumor necrosis and extensive vascular 
damage (Sgadari C., et al, 1997). Similar antitumor effects have been observed by 
use of tumor cells genetically engineered to express IP-10 (Angiolillo A.L., et al, 
1995). 
       
As previously described for DLD1 cells, IFNγ-dependent induction of iNOS was 
similarly impaired by pretreatment with NO (Cavicchl M., et al. 2000). Supression of 
iNOS expression should serve to control overproduction of NO that may be 
deleterious. However, effects of NO on iNOS protein appear to be species and 
stimulus dependent, as expression of this enzyme in response to IL-1β is potently 
enhanced by NO in rat mesangial cells or smooth muscle cells (Fig.5c) (Mühl H., et 
al. 1995; Boese M., et al.1996). These results suggest that NO may be able to 
specifically downregulate cellular responses to IFNγ in DLD-1 cells. This notion 
concures with a report that demonstrates the capability of NO to interfere with 
activation of STAT-1 (Llovera M., et al. 2001), a pivotal component of IFNγ signaling.  
Taken together, NO differentially regulated expression of modulators of angiogenesis 
in DLD-1 colon carcinoma cells. Production of tumor promoting IL-8 and VEGF was 
amplified, whereas in the same cells expression of tumorstatic IP-10 and MIG was 
efficiently downregulated by NO. IP-10 and MIG are supposed to be key mediators of 
IFNγ mediated tumor regression (Belperio, J.A., et al. 2000). The regulatory function 
of NO may contribute to the phenomenon of tumor promotion by NO. The present 
data are in accord with reports on control of colon carcinogenesis in rodents by 
blockage of iNOS activity (Kisley L.R., et al. 2002; Rao C.V., et al. 1999)  and further 
support the concept of iNOS inhibition as a therapeutic strategy for the treatment of 
human cancer. 
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5 Summary  
 
Interleukin (IL)-8, heme oxygenase-1 (HO-1), and vascular endothelial growth factor 
(VEGF) appear to be critically involved in immune responses associated with 
inflammation, infection, and tumor growth. Regulation of these mediators was studied 
in the human colon carcinoma cell line DLD-1. Here we report that pyrrolidine 
dithiocarbamate (PDTC) not only augmented tumor necrosis factor-α induced release 
of IL-8, but also mediated IL-8 expression as a single stimulus. Mutational analysis of 
the IL-8 promotor and electrophoretic mobility shift analysis revealed that activation of 
the transcription factor activator protein-1 (AP-1) and a constitutive nuclear factor-κB 
(NF-κB) binding activity in DLD-1 cells were mandatory for PDTC-induced IL-8 
expression. Besides IL-8, PDTC also upregulated expression of HO-1 and VEGF in 
these cells. Induction of IL-8 by PDTC was not restricted to DLD-1 cells, but was 
observed as well in Caco-2 colon carcinoma cells and in peripheral blood 
mononuclear cells. PDTC is currently advocated for use as chemotherapeutic drug in 
the treatment of certain malignancies, among them colorectal cancer. Induction of IL-
8, HO-1, and VEGF may affect therapeutic applications of this agent. 
Expression of inducible nitric oxide (NO) synthase and production of NO appears to 
be a marker of tumor progression in human neoplasia, among them melanoma, head 
and neck cancer, and colorectal cancer. Since tumor-promoting functions of NO have 
been associated with increased angiogenesis at the tumor site, we investigated 
effects of NO on the production of selected chemokines that are supposed to 
differentially regulate tumor growth, namely proangiogenic IL-8 as well as 
tumorsuppressive interferon-inducible protein-10 (IP-10) and monokine induced by 
interferon-γ (MIG). These chemokines are expressed by colon carcinoma cells after 
stimulation with the combination IL-1β/Interferon (IFN)γ. Under these conditions, 
release of IL-8 was exclusively mediated by IL-1β but not by IFNγ, whereas 
production of IP-10 and MIG was dependent on activation by IFNγ. Effects of NO 
were analyzed by incubation with the NO-donor DETA-NO. Expression and release 
of IL-8 from colon carcinoma cells was markedly upregulated by NO. In addition, NO 
enhanced gene expression of vascular endothelial growth factor (VEGF). 
Accordingly, basal release of VEGF was significantly augmented in cells exposed to 
NO. In contrast, IL-1β/IFNγ-induced production of IP-10 and MIG was suppressed by 
NO. Likewise, overproduction of IFNγ-dependent inducible NO synthase was 
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restrained by NO in DLD-1 cells. The present data are consistent with previous 
observations that relate NO to enhanced tumor angiogenesis and imply that 
NO-mediated upregulation of IL-8 and VEGF as well as downregulation of IP-10 and 
MIG expression may contribute to this phenomenon. 
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7 Appendix  
 
7.1 Abbreviations 
Chemicals and bioactive compounds 
 
AP-1    activator  protein-1 
BSA    bovine  serum  albumin 
bZIP    basic  region-leucine  zipper 
C/EBP  CCAAT/enhancer-binding protein 
CIP1    cyclin-dependent  kinase-interacting protein 1 
DMEM    Dulbecco’s modified Eagle’s medium 
ECL    enhanced  chemiluminescence   
EDRF    endothelium-derived relaxing factor 
EDTA    ethylendiamin-N,N,N’,N’-tetraacetat 
ELISA    enzyme-linked  immunosorbent  assay 
EMSA     electrophoretic mobility shift assay 
eNOS    endothelial  NOS 
FCS      fetal  calf  serum 
FU    fluro  uracil 
GSNO    S-nitroso-glutathione 
HIF-1α    hypoxia inducible factor-1α 
HO-1    heme  oxygenase-1 
IFNγ    interferon  gamma 
IκB    inhibitors  of  NF-κB 
IL    interleukin 
iNOS      inducible nitric oxide synthase 
IP-10      interferon gamma inducible protein-10 
JNK      c-Jun N-terminal kinase  
LB    Luria  Bertani 
LDH      lactat  dehydrogenase 
L-NAME   (L)-N
G-nitroarginine methylester  
LPS    lipo-poly  sacharide 
MAPK    mitogen-activated  protein  kinase 
MEKK     MAP kinase kinase kinase  
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MHC    histocompatibility  complex  class 
MIG      monokine induced by interferon gamma 
MIP    macrophage  inflammatory  protein 
MKK    MAP  kinase  kinase 
NF-κB      nuclear factor kappa B 
NK    natural  killer 
NLS    nuclear  localization  signal 
nNOS    neuronal  NOS   
NO    nitric  oxide 
NOS    nitric  oxide  synthases 
ONOO(-)   peroxinitrite 
PBMC    peripheral  mononuclear blood cells 
PBS      phosphate  buffered  saline 
PDTC    pyrrolidine  dithiocarbamate 
PmxB    polymyxin-B 
PVDF    polyvinylidene  fluoride 
RHD    Rel  homology  domain 
RLUs    relative  light  units 
ROI    reactive  oxigen  intermediates 
ROS    reactive  oxygen  species 
SAPK     stress-activated protein kinase 
SDS    sodium  dodesyl  sulfate 
SLC       secondary lymphoid organ cytokine 
SNAP    S-nitroso-N-acetylpenicillamine 
SNP    sodium  nitroprusside 
Stat 1     signal transducer and activator of transcription 1 
TNFα   tumor  necrosis  factor  alpha 
VEGF     vascular endothelial growth factor 
WAF1    wild-type  p53-activated fragment 1 
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7.5 Die Regulation des Tumorwachstums in Dickdarmkrebszellen 
wird beeinflusst von Stress ausgelöst durch PDTC und NO 
(Deutsche Zusammenfassung) 
 
 
 
7.5.1Einleitung 
 
Krebs ist eine verheerende Krankheit mit weltweit etwa 5,2 Millionen Todesopfern pro 
Jahr. Bei dieser Krankheit versagen Standardtherapiemethoden häufig  (Parkin, D.M, 
et al. 1999). Neue Therapieansätze sind antiangiogene Pharmaka und 
Immuntherapeutische Ansätze gegen Tumore. Die Entwicklung neuer Therapien 
beruht zum Teil auf in jüngster Zeit erworbenen Kenntnissen über Zytokine und 
Chemokine (Belperio, J.A. et al. 2000; Fushimi, T. et al. 2000; Sharma, S. et al. 
2000). 
 
 
7.5.1.1 Zytokine 
 
Zytokine sind kleine Proteine, meist Glykoproteine mit einem Molekulargewicht von 8 
bis 40 kD. Sie fungieren als biochemischer Botenstoff zwischen Zellen. Das Wort 
Zytokin leitet sich aus den griechischen Wörtern für Zelle und Kinese ab.  
Die Zytokine sind im Organismus bei einer Reihe von Prozessen involviert. Dazu 
gehören: Regulation der Immunantwort, Zellwachstum/-differenzierung und die 
Reparatur/Wiederherstellung von Gewebe.  
Ein einzelnes Zytokin kann eine Vielzahl von verschiedenen biologischen Aktivitäten 
auslösen. Die meisten Zytokine werden von Leukozyten synthetisiert und wirken 
auch auf diese.  Dies ist der Grund, warum die Zytokine bis heute auch noch als 
Interleukine bezeichnet werden.  Diese Namensgebung wiederspiegelt jedoch nicht 
die biologische Realität, da man heute weiß, daß mit Hilfe dieser Botenstoffe auch 
Signale zwischen anderen Zelltypen übertragen werden. Die Fähigkeit von Zytokinen 
auf verschiedene Zelltypen zu wirken und dabei verschiedene biologische Effekte 
hervorzurufen, nennt man auch Pleiotropismus.  
Synthese und die Wirkungsweise von Zytokinen werden durch andere Zytokine 
wiederum beeinflusst. Einige besitzen die Fähigkeit, sich in ihrer Wirkung zu 
ergänzen oder zu verstärken; während andere sich in ihrer Wirkung gegenseitig 
abschwächen. 
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Des weiteren besitzen Zytokine die Eigenschaft, die Synthese weiterer Zytokine zu 
induzieren, wodurch eine „Zytokin-Signal-Kaskade“ in Gang gesetzt werden kann. 
Dies kann bedeuten, daß für die Übertragung von einem biologischen Effekt durch 
ein Zytokin mehrere Zytokine benötigt werden.  
Diese Effekte werden durch spezifische membrangebundene Rezeptoren 
übertragen. Die Expression von Zytokinrezeptoren ist ein wichtiger regulatorischer 
Faktor in der Zytokinbiologie. Festzuhalten ist, die Sekretion eines Zytokines ist von 
kurzer Dauer und selbst limitierend. Für die Produktion eines Zytokins ist 
normalerweise eine transiente Induktion der de novo Gentranskription erforderlich.  
Eine Induktion der Gentranskription kann ausgelöst werden durch Stress oder 
immunologische Signale.  
Entsprechend ihrer Einflüsse auf entzündliche Prozesse kann man die Zytokine in 
pro- und antientzündliche Zytokine einteilen. 
Im Gegensatz zu antientzündlichen Zytokinen können proentzündliche in manchen 
Fällen das Krankheitsbild verschlechtern. Die antientzündlichen Zytokine haben die 
Funktion, die Entzündung zu hemmen und den Heilungsprozess zu fördern.  
In einem gesunden Organismus sind nur geringe Konzentrationen der 
proentzündlichen Zytokine zu finden.  Werden sie jedoch in höheren Konzentrationen  
sezerniert, so wird von ihnen eine Reihe von Genprodukten induziert. Hierzu gehören  
die induzierbare Stickstoffmonoxid-Synthase (NOS) und das Interleukin-8 (IL-8).  
Dies führt letztendlich zu den Symptomen einer Entzündung, zu denen Rötungen, 
Schwellungen, Schmerz, Funktionsverlust und Zerfall des Gewebes gehören 
(Dinarello C.A. and Moldawer L.L., 2000; Janeway C.A. and Travers P., 1997; Abbas 
A., 2000).     
Proentzündliche Zytokine aktivieren eine Reihe von wichtigen Transkriptionsfaktoren; 
diese sind unter anderen NF-κB, AP-1 und NF-IL-6. 
Ein besonders wichtiges Zytokin ist das Interferon-γ (IFN−γ). Dies ist ein 
homodimeres Glykoprotein mit pleiotropher immunologischer Funktion bei der 
zellvermittelten Immunität gegen intrazelluläre Mikroben. IFN−γ kann die 
antimikrobielle Wirkung von Makrophagen verstärken, indem die Synthese von 
reaktiven Sauerstoffzwischenprodukten und Stickoxiden stimuliert wird (Stark, G.R. 
et al, 1998; Bach E. et al, 1997).  
Neben der bedeutenden Funktion bei der Immunabwehr hat das IFN−γ auch eine 
wichtige Funktion als tumorhemmendes Zytokin. Die Interferon-γ Signalkaskade führt 
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zur Apoptose und zur Expression von immunmodulierdenden Proteinen, wie dem 
Interferon induzierbares Protein-10 (IP-10),  dem Monokin induziert durch Interferon-γ 
(MIG) und der iNOS, die in Zusammenarbeit mit T-Zellen Tumore zerstören können 
(Ikeda H., et al, 2002).     
 
 
7.5.1.2 Chemokine 
 
Chemokine sind sind kleine Proteine, meist Glykoproteine, mit einem 
Molekulargewicht von 8 bis 17 kD. Es sind Zytokine, welche chemotaktische 
Reaktionen von Zellen induzieren und die Angiogenese regulieren.  
Durch die Wirkung von Chemokinen sind Leukocyten in der Lage, sehr schnell auf 
Infektionen zu reagieren. Die Interaktion von chemotaktisch wirksamen Substanzen 
mit Leukocyten initiiert eine Reihe von biochemischen und zellulären Ereignissen. 
Hierzu gehören im einzelnen, die Veränderung von Ionenströmungen,  Veränderung 
der Zellformen, die Sekretion lysosomaler Enzyme sowie die Produktion von 
Superoxidradikalen und eine bessere Beweglichkeit der Zellen.  
Die Chemokine können aufgrund ihrer molekularen Struktur in vier Gruppen eingeteilt 
werden. Dies sind die CXC, CX3C, CC und C Chemokine.  Diese Bezeichnung 
beruht auf einer hoch konservierten Struktur zweier nahe beeinander stehenden 
Aminosäuren (Cystein) in der Aminosäurekette (Dinarello C.A. and Moldawer L.L., 
2000; Janeway C.A. and Travers P., 1997; Abbas A., 2000). Die spezifischen Effekte 
der Chemokine werden durch transmembranäre G-Protein gekoppelte Rezeptoren 
vermittelt (Murphy PM.,1994). 
Ebenso, wie bei den Zytokinen, kann man die Chemokine aufgrund ihrer Funktion 
einordnen. Wie schon im Falle der Zytokine, wo eine Verschiebung der 
Konzentrationen der anti- zu den proentzündlichen Zytokinen das Krankheitsbild der 
Infektion beeinflusst, ist etwas ähnliches im Falle der Chemokine in Bezug auf die 
Angiogenese möglich.    
Chemokine beeinflussen den Tumor durch drei wichtige Mechanismen: Regulation 
der tumorassozierten Angiogenese, Aktivierung einer organismus- und 
tumorspezifischen Immunantwort und durch die direkte Stimmulation des 
Tumorwachstums als autokriner Faktor. 
Angiogenese ist das Wachstum neuer oder bereits existierender Blutgefäße  sowie 
von Mikrokapillaren. Normalerweise findet dieser Prozess während der 
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Embryonalentwicklung oder der Wundheilung statt; man findet dieses Phänomen 
aber auch in allen größeren Tumoren.  
Chemokinen werden bei der Angiogenese entscheidende Bedeutung beigemessen, 
daher teilt man sie auch in pro- und antiangiogene Chemokine ein. In gesundem 
Gewebe herrscht ein Gleichgewicht zwischen pro- und antiangiogenen Chemokinen. 
Wird das Gleichgewicht durch einen äußeren Einfluss gestört, z.B. zugunsten der 
proangiogenen Chemokine, so wird ein Tumorwachstum begünstigt (Belperio J.A. et 
al, 2000; Moore B.B., et al, 1998).  
 
 
7.5.1.3 Stickstoffmonoxid (NO) 
 
NO ist ein weiteres wichtiges Signalmolekül, das in vielen verschiedenen Geweben 
eine Reihe physiologischer Prozesse reguliert. Dazu gehören Vasodilatation, 
neuronale Funktion, Entzündung und die Immunantwort. NO hat nur eine sehr kurze 
Halbwertzeit von einigen Sekunden. Es wird mit Hilfe eines Enzyms mit dem Namen 
NOS hergestellt. Dieses Enzym convertiert Arginin und O2 in Citrullin und NO. 
NADPH ist ein notwendiger Co-Faktor. 
NO vermittelt eine Vielzahl biologischer Effekte. Daher ist es auch verständlich, daß 
eine Dysregulation der NOS, die verantwortlich ist für eine Reihe von biologischen 
Prozessen, zu einer Vielzahl verschiedener Krankheiten führen kann (Kolb J.P., 
2000).    
 
 
7.5.2 Ziel der Untersuchungen 
 
Es wurde die Expression verschiedener Parameter der Angiogenese in aktivierten 
DLD-1 Kolonkarzinom Zellen untersucht. Um diese Zellen zu aktivieren wurden zwei 
Stimuli verwendet.  
Im ersten Teil der Studie wurden die Zellen Pyrrolidine-Dithiocarbamate (PDTC) 
ausgesetzt. PDTC ist ein AP-1 aktivierendes Reagenz, welches für die Behandlung 
von Darmkrebs in Kombination mit Zytostatika vorgeschlagen wurde  (Chinery, R., 
1997; Bach, S.P.2000;  Della Ragione, F. 2000). 
Im zweiten Teil wurden Effekte von NO, welches ein immunmodulierendes Radikal 
ist, untersucht. NO wird enogen im unmittelbaren Umfeld des Tumors produziert.   
121                                                                                                                       Appendix 
Die Expression der induzierbaren Stickoxidsynthase und die Produktion von 
Stickoxid (NO) korreliert mit der Angiogenese bei verschiedenen Krebserkrankungen 
(Melanome, Tumore im Hals und Kopfbereich und Darmkrebs) (Thomsen, L.L., et al. 
1995; Cobbs, C.S.,et al.1995; Klotz, T., et al. 1998Liu, C.Y., et al. 1998; Thomsen, 
L.L.,et al. 1998; Gallo 0., et al. 1998). 
Da tumorbegünstigende Funktionen von NO mit vermehrter Angiogenese in 
Verbindung gebracht werden (Jenkins, D.C., et al 1995; Ambs, S., et al. 1998), 
wurden die Effekte von NO hinsichtlich der Produktion von ausgesuchten 
Chemokinen, die an der Steuerung des Tumorwachstums beteiligt sind, untersucht. 
 
 
7.5.3 Untersuchungen und Ergebnisse 
 
Der Produktion von  Interleukin-8 (IL-8), Häm Oxygenase-1 (HO-1), und dem 
vaskulären endothelialen Wachstumsfaktor (VEGF) wird zunehmend größere 
Bedeutung im Rahmen der Regulation der Immunantwort bei Entzündung, Infektion 
und Tumorwachstum zugemessen (Mitchell J.F., et al. 2001; Ferrara, N. et al. 1999; 
Doi, K., et al. 1999 ; Nishie, A., et al. 1999). Ziel dieser Arbeit war die Untersuchung 
der Regulation dieser Botenstoffe in vitro durch Verwendung der humanen Dickdarm 
Karzinom Zellinie DLD-1. Die Substanz Pyrrolidine Dithiocarbamate (PDTC) verstärkt 
nicht nur die durch Tumor Nekrose Faktor-α (TNF-α) vermittelte Ausschüttung von 
IL-8, sondern induziert auch als alleiniger Stimulus die IL-8 Sekretion. 
Mutationsanalysen des IL-8 Promotors und „Electrophoretic Mobility Shift“ 
Untersuchungen (EMSA) zeigten, daß die Aktivierung des Transkriptionsfaktors AP-1 
(Aktivator Protein-1) und die Bindungsaktivität von konstitutiv aktiviertem Nuclear 
Faktor-κB (NF-κB) in DLD-1 Zellen für die PDTC induzierte IL-8 Expression 
zwingend erforderlich waren. Weiterhin war PDTC in der Lage in DLD-1 Zellen neben 
IL-8 auch die Expression von HO-1 und VEGF zu verstärken. Die Induktion von IL-8 
durch PDTC war nicht nur auf DLD-1 Zellen beschränkt, sondern wurde auch in 
Caco-2 Zellen (ebenfalls Dickdarmkrebszellen) und in humanen mononukleären 
Blutzellen beobachtet. Die Verwendung von PDTC wird seit kurzem als 
Kozytostatikum für die Behandlung von verschiedenen bösartigen Tumoren, unter 
ihnen auch Darmkrebs, vorgeschlagen (Chinery, R., 1997; Bach, S.P.2000;  Della 
Ragione, F. 2000). Aus unseren Versuchen läßt sich ableiten, daß die Induktion von 
IL-8, HO-1 und VEGF die therapeutische Anwendung dieser Substanz nachteilig 
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beeinflussen könnte. Dies ergibt sich daraus, daß die Faktoren IL-8 und VEGF durch  
ihre proangiogene Wirkung und die HO-1 durch ihre antiapoptotische Wirkung das 
Tumorwachstum fördern.  
Die Expression der induzierbaren Stickoxidsynthase und die Produktion von 
Stickoxid (NO) korreliert mit der Angiogenese bei verschiedenen Krebserkrankungen 
darunter Melanome, Tumore im Hals und Kopfbereich und Darmkrebs (Thomsen, 
L.L., et al. 1995; Cobbs, C.S.,et al.1995; Klotz, T., et al. 1998; Liu, C.Y., et al. 1998; 
Thomsen, L.L.,et al. 1998; Gallo 0., et al. 1998). Da tumorbegünstigende Funktionen 
von NO mit vermehrter Angiogensese in Verbindung gebracht werden (Jadeski, L.C., 
and Lala, P.K. 1999; Kerbel, R.S. 2000), wurden die Effekte von NO hinsichtlich der 
Produktion von ausgesuchten Chemokinen, die an der Steuerung des 
Tumorwachstums beteiligt sind, untersucht. Zu diesen Chemokinen gehören das 
proangiogene IL-8 (Koch, A.E., et al. 1992) sowie das tumorsuppressive Interferon 
induzierbare Protein-10 (IP-10) (Luster, A.D.,  et al. 1995) und das Monokin induziert 
durch Interferon-γ (MIG) (Addison C.L., et al. 2000). Diese Chemokine werden, nach 
Stimulation mit IL- 1β und Interferon-γ (IFN-γ) von DLD-1 Zellen, ausgeschüttet. Unter 
diesen Bedingungen wird die IL-8 Freisetzung alleine durch IL-1β vermittelt nicht  
aber durch INFγ.  Im Gegensatz zu IL-8 hängt die Sekretion von IP-10 und MIG von 
der Aktivierung durch IFNγ ab. Die Effekte von NO wurden analysiert indem DLD-1 
Zellen mit dem NO-Donor DETA-NO inkubiert wurden. DETA-NO besitzt eine 
Halbwertzeit von 16,5h und simuliert damit die Effekte der NOS. Synthese und 
Freisetzung von IL-8 wurden durch die Behandlung mit NO stark gesteigert. 
Außerdem wurde in Zellen die dem NO-Donor ausgesetzt wurden die basale 
Sekretion des VEGF signifikant verstärkt. Dies steht im Gegensatz zur IL-1β/IFNγ-
induzierten  Produktion von IP-10 und MIG, beide wurden durch Koinkubation mit NO 
unterdrückt. Ebenso wurde die Expression der IFNγ abhängigen iNOS in DLD-1 
Zellen von NO unterdrückt. Die vorliegenden Daten ergänzen vorherige Studien, in 
denen NO mit Tumorangiogenese und verstärkten Tumorwachstum in Verbindung 
gebracht wird. Die NO vermittelte Induktion von IL-8 und VEGF, ebenso wie die 
Verminderung der IP-10 and MIG Expression, könnte zu diesem Phänomen 
beitragen. Unsere Studien stützen die Hypothese, daß spezifische Inhibitoren der 
iNOS therapeutischen Nutzen bei humanen Neoplasien haben könnten. 
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